



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Detection of pulmonary nodules: comparison of ultra-low dose chest CT and standard low-dose CT. A monocentric, prospective, non-randomized, comparative, open-label study with blind reading of outcomes.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025661
Article Type:	Protocol
Date Submitted by the Author:	10-Aug-2018
Complete List of Authors:	<p>Ludwig, Marie; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine</p> <p>Chipon, Emilie; INSERM, CIC 1406; Centre Hospitalier Universitaire Grenoble Alpes, pôle recherche</p> <p>Cohen, Julien; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine</p> <p>Reymond, Emilie; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie</p> <p>Medici, Maud; INSERM, CIC 1406; Centre Hospitalier Universitaire Grenoble Alpes, pôle recherche</p> <p>Cole, Anthony; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine</p> <p>Moreau Gaudry, Alexandre; INSERM, CIC 1406; Centre Hospitalier Universitaire Grenoble Alpes, pôle recherche</p> <p>Ferretti, Gilbert; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine</p>
Keywords:	low dose computed tomography, ultra low dose computed tomography, pulmonary nodule, lung cancer screening, iterative reconstruction

SCHOLARONE™
Manuscripts

Detection of pulmonary nodules: comparison of ultra-low dose chest CT and standard low-dose CT. A monocentric, prospective, non-randomized, comparative, open-label study with blind reading of outcomes.

M Ludwig, E Chipon, J Cohen, E Reymond, M Medici, A. Colé, A.Moreau-Gaudry, G R Ferretti

Corresponding author:

Marie Ludwig

Service de radiologie diagnostique et thérapeutique

CHU Grenoble Alpes

CS 10217

38043 Grenoble CEDEX 9

France

mludwig@chu-grenoble.fr

+33 476769290

Affiliations E. Chipon /M.Medici

INSERM, CIC 1406, F-38000 Grenoble, France

Université Grenoble-Alpes, CIC 1406, F-38000 Grenoble, France

CHU Grenoble-Alpes, Pôle Recherche, F-38000 Grenoble, France

Affiliations A.Moreau-Gaudry

Université Grenoble-Alpes, CNRS, Grenoble INP, TIMC-IMAG, F-38000 Grenoble, France

INSERM, CIC 1406, F-38000 Grenoble, France

CHU Grenoble-Alpes, Pôle Recherche, F-38000 Grenoble, France

CHU Grenoble-Alpes, Pôle Santé Publique, F-38000 Grenoble, France

Affiliations *G.R. Ferretti, M Ludwig, J Cohen, E Reymond, A.Cole*

Université Grenoble-Alpes, F-38000 Grenoble, France

Service de radiologie diagnostique et thérapeutique, CHU Grenoble Alpes, CS 10217, 38043

Grenoble CEDEX 9, France

Sponsor:

Delegation to Clinical Research and Innovation (DRCI) of Grenoble-Alpes University Hospital

CHU Grenoble-Alpes, Pôle Recherche, F-38000 Grenoble, France

+33476767575

KEYWORDS

Low dose computed tomography, Ultra low-dose computed tomography, pulmonary nodule, Lung

cancer screening, iterative reconstruction

Word count, excluding title page, abstract, article summary, references, figures, tables, and acknowledgements : 3976

ABSTRACT

Introduction:

Lung cancer screening in individuals at risk has been recommended by various scientific institutions. One of the main concerns for CT screening is repeated radiation exposure, with the risk of inducing malignancies in healthy individuals. Therefore, lowering the radiation dose is one of the main objectives for radiologists. The aim of this study is to demonstrate that an ultra-low dose (ULD) chest CT protocol, using recently introduced hybrid iterative reconstruction (ASiR-V, GE medical Healthcare, Milwaukee, WI, USA), is as performant as a standard “low dose” (LD) CT to detect non calcified lung nodules $\geq 4\text{mm}$.

Methods and analysis:

The total number of patients to include is 150. Those are referred for non-enhanced chest CT for detection or follow-up of lung nodule and will undergo an additional unenhanced ULD CT acquisition, the dose of which is on average 10 times lower than the conventional LD acquisition. Total dose of the entire exam (LD + ULD) is lower than the French diagnostic reference level for a chest CT (6.65 milliSievert). ULD CT images will be reconstructed with 50% and 100% ASiR-V, and LD CT with 50%. The 3 sets of images will be read in random order by two pair of radiologists, in a blind test, where patient identification and study outcomes are concealed. Detection rate (sensitivity) is the primary outcome. Secondary outcomes will include concordance of nodule characteristics; inter-observer reproducibility; influence of subjects’ characteristics, nodule location, and nodule size; and concordance of emphysema, coronary calcifications evaluated by visual scoring and bronchial alterations between LD and ULD CT. In case of discordance, a third radiologist will arbitrate.

Ethics and dissemination:

The study was approved by the relevant ethical committee. Each study participant will sign an informed consent form.

Trial registration number: *Clinicaltrials.gov* NCT03305978

ARTICLE SUMMARY:**STRENGTHS AND LIMITATIONS OF THIS STUDY**

- We will evaluate the sensitivity of an ultra-low dose CT, delivering 10 times less radiation than conventional low-dose CT, to detect lung nodules, in a French population of 150 patients referred for lung nodule check-up or follow-up.
- We will use a recently introduced hybrid iterative reconstruction (ASiR-V) and different levels of ASIR-V will be assessed
- Nodules characteristics will be analyzed in particular the diagnosis of intrapulmonary lymph node, which is a benign lesion.
- Patients with morbid obesity (BMI>35) will not be included as image quality of ultra-low dose CT is not acceptable for those morphotypes.
- Readers will be aware of the type of CT acquisition (LD and ULD) and reconstruction, because they are easily recognizable due to the different level of image noise.

93 INTRODUCTION

94 Lung cancer is the deadliest cancer in the world (1), mainly due to the fact that it is often diagnosed
95 at advanced stages that are not surgically curable. The current challenge is therefore to detect lung
96 cancer at early asymptomatic stages. Risk factors such as smoking and occupational exposure
97 (mainly asbestos, silica, arsenic, chromium, iron, coal, ionising radiation) are well known and
98 enable to define the target population for such programs.

99 The National Lung Screening Trial (NLST) was the first study to show that a low dose (LD)
100 (average effective dose of 1.5mSv) computed tomography (CT) lung cancer screening reduced
101 specific death by 20% (95% CI, 6.8 to 26.7; P=0.004) as compared with chest X Ray (CXR)
102 screening (single-view posteroanterior) in actual or former smokers (>30 pack years) patients
103 between 55 and 74 years old (2).

104 Other lung cancer screening studies are still in progress in Europe, such as the NELSON study in
105 Belgium and the Netherlands, the results of which are expected to be reported soon (3)

106 However, the drawback of using LD CT at such doses (<1.5 millisievert (mSv)) is that even though
107 irradiating less than standard chest CT, the radiation exposure is still on average 10 times higher
108 than a 2 views CXR, and may be a risk for induced malignancies in itself. (4)

109 In this context, great efforts are currently being made by CT manufacturers to reduce the dose and
110 maintain diagnostic quality. Technologies such as automated exposure control, lower tube current
111 and iterative reconstruction (5), were recently introduced, enabling further dose decrease for chest
112 CTs, and the concept of “ultra-low dose (ULD) CT” (or submillisievert CT), which delivers a
113 radiation dose approaching that of 2 CXR views at the cost of a slight deterioration of the image
114 quality (6) . Among these technological advances, the most significant is probably the new iterative
115 reconstruction whether full iterative or hybrid. (7,8,9,10)

116 Promising results have been published for lung nodule detection with ULD CT (11,12,13).
117 However, these studies were conducted on Asian populations, which may have different
118 morphotypes compared to Caucasian populations.

Huber and al. performed a phantom study comparing standard, LD and ULD CT for detection of pulmonary nodules. When compared to standard CT, the detection rate was 95.5% for LD CT (1.76 mSv), and 93.3% for ULD CT (0.13mSv), increasing at 97.5% when adding computer aided diagnosis and maximal intensity projection (14).

Since we started to design our study protocol, Messerli and al. published a study including 202 patients referred for any clinically indicated chest CT. 91.2% nodules were detected using ULD CT (0.13 \pm 0.01mSv) as compared to LD CT (1.8 \pm 0.7 mSv). Sensitivity was significantly higher for larger nodule diameter, lower BMI patients, lower image noise and for solid and calcified nodules (15).

Neroladaki and al. showed the same number of detected nodules between an ULD acquisition (0.16 \pm 0.006mSv) with iterative reconstruction and a standard dose filtered back projection acquisition (11.2 \pm 2.7mSv), and more nodules detected with model based iterative reconstruction (MBIR) than adaptive statistical iterative reconstruction (ASIR) (16). MBIR is known to better minimize image noise compared to ASIR : Ichikawa and al found a significantly lower image noise with LD (1.6 \pm 0.8 mSv) MBIR CT (11.6 \pm 1.0 Hounsfield units (HU)) than with LD ASIR CT (21.1 \pm 2.6 HU, $p < 0.0005$), a slightly better image quality score for decreased lung attenuation lesion, and no difference in image quality scores for consolidation or mass, ground-glass attenuation, or reticular opacity with MBIR compared to ASIR LD CT (8). But MBIR may slightly deteriorate lesion margin (9), and significantly increases reconstruction time, taking more than 30 minutes, when patients lie less than 10 minutes in the machine. ASIR-V is the latest generation of hybrid iterative reconstruction (GE medical Healthcare, Milwaukee, WI). It combines ASIR and MBIR and enables a better noise reduction than ASIR, with a processing time of only few minutes, suitable to a routine chest CT session (17).

According to the ALARA (as low as reasonably achievable) principle, we hope to validate our ULD chest CT protocol (<0.2mSv), the dose of which is 10 times lower than a usual LD CT, as a

sensitive tool to detect lung nodules. Thus, this ULD CT acquisition could be generalized for lung nodules detection and would consolidate the setup of lung cancer screening programs. Also, this would allow the generalization of ULD protocols, for radiation sensitive populations (children and young adults in particular).

METHODS AND ANALYSIS

Study design and objectives

The objectives of this study are to evaluate the performance of ULD CT for the detection of lung nodules, and the evaluation of nodule characteristics in comparison to LD CT. Furthermore, as smoking is a common risk factor, performance for the detection of cardiac and respiratory associated diseases (bronchial abnormalities, emphysema, coronary calcifications) is also evaluated. An additional ULD CT is performed in patients referred for non-enhanced chest CT for lung nodules check-up or follow-up. The dose delivered with both acquisitions is still lower than the French diagnostic reference level (6.65mSv). We chose to only include nodules ≥ 4 mm as the incidence of cancer is very low below this threshold, and are not currently considered as clinically significant (18). A 4 mm threshold was also used for the NLST study (2). In addition, fully calcified nodules are excluded from the analysis because they are constantly benign and easily detected. We will study nodule subtypes (solid, part-solid and pure ground-glass) and size. Furthermore we will evaluate the performance of ULD CT to diagnose intrapulmonary lymph nodes, which are benign nodules not needing follow up (19), and were not analyzed in previous ULD CT studies. This trial sponsored by the Grenoble-Alpes University Hospital (CHUGA, France) is designed as a monocentric, prospective, non-randomized study in which the patient is his own control. All outcomes are evaluated by blinded double reading. Patient enrollment started in October 2017 and is expected to be completed in September 2018. Figure 1 summarizes the process of inclusion, intervention and reading, described in detail below.

Primary outcome

Detection rate (sensitivity) of lung nodules in ULD chest CT using the conventional chest LD CT as gold-standard.

Secondary outcomes

1) Diagnostic criteria: true positive (TP), false positive (FP), true negative (TN), false negative (FN), positive predictive value (PPV), negative predictive value (NPV), Specificity (Sp) of ULD CT

2) Concordance of nodule's size, subtype, and diagnosis of typical intrapulmonary lymph node among lung nodules between ULD and LD CT

3) Inter-observer reproducibility for size, subtype and diagnosis of lung nodules in ULD CT

4) Influence of subjects characteristics (age, sex, BMI), nodule location, and nodule size on lung nodule detection with ULD CT

5) Concordance of emphysema detection, type and distribution between ULD and LD CT

6) Concordance of Weston score of coronary calcifications between ULD and LD CT

7) Concordance of visual assessment of bronchial thickening, mucoid impaction or dilatation between ULD and LD CT

Eligibility Criteria

Inclusion criteria

- aged 18 years or older
- referred for non-enhanced chest CT for the following indications:
 - lung nodule check-up or follow-up
 - nodular abnormality on chest X ray
 - morphologic assessment of chronic obstructive pulmonary disease (COPD) or emphysema
 - asbestos exposure
 - assessment before lung radio frequency ablation

- 1
- 2197- assessment of disease extent of an extra thoracic cancer (in case of iodinated
- 3
- 4198 intravenous contrast agent contraindication)
- 5
- 6199- Check-up before extra-thoracic transplantation (in case of iodinated intravenous
- 7
- 8200 contrast agent contraindication).
- 9

10201 Exclusion criteria

11

- 12202
 - Inability to lie down and stay still during the examination
- 13
- 14203
 - Inability to hold breath for more than 5 seconds
- 15
- 16204
 - Pneumonia in the last 3 months
- 17
- 18205
 - Body mass index (BMI) more than 35kg/m²
- 19
- 20206
 - Pregnant or breastfeeding women
- 21
- 22
- 23
- 24207
- 25
- 26208
- 27

28209 **CT scan acquisitions and reconstructions**

29

30210 The LD and ULD acquisitions are performed on the Revolution CT scanner (GE medical

31

32211 Healthcare, Milwaukee, WI, USA) equipped with the third generation ASIR-V iterative

33

34212 reconstruction. Acquisitions are performed successively in the same CT exam, in the supine

35

36213 position and at suspended full inspiration. Both acquisitions cover the same pulmonary fields from

37

38214 the apex to the costo-diaphragmatic angle, determined on the scout views (2 views).

39

40

41215 The LD acquisition is the reference exam for the diagnosis of pulmonary nodules. The acquisition

42

43216 parameters are: spiral CT scanning; 120kVp; automatic modulation of 3D radiation dose (“Smart

44

45217 mA”+ Organ Dose Modulation) with lower bound 100mA, maximal bound 200mA and noise index

46

47218 10; rotation time: 0.35sec ; modulation 35-70 mAs; pitch = 0.992 :1 and collimation: 80mm. The

48

49219 radiation dose, CTDIvol (volume CT dose index) and DLP (Dose Length Product = CTDIvol x

50

51220 length of exposure) may vary depending on patient attenuation and length of the acquisition. The

52

53221 expected DLP is between 70 and 200mGy.cm (0.98mSv to 2.8mSv) (the effective dose is calculated

54

55

56

57

58

59

60

by multiplying DLP by a thoracic conversion factor of 0.014 (20)), for an average DLP of 100mGy.cm.

The ULD CT acquisition parameters are: spiral CT scanning; 120kVp; fixed tube current of 10mA; rotation time: 0.35s; 3.5 mAs; pitch: 0.992 :1, collimation: 80mm. These parameters are fixed for all patients. The CTDIvol is constant at 0.24mGy. The DLP will depend only on the length of the acquired chest, different for each patient, expected around 10mGy.cm (0.14mSv). The modulation of the mA is deactivated to allow a very low tube current and therefore an ULD acquisition. The ULD acquisition increases the exam time by up to two minutes.

The reconstruction parameters are identical for both acquisitions: slice thickness: 1.25mm; standard filter and lung filter; contiguous 8-mm thickness Maximal Intensity projection (MIP) reconstruction, and iterative reconstruction with different percentages. We use ASIR-V in our study which is the latest generation of iterative reconstruction techniques. It blends hybrid iterative reconstruction and standard filtered back projection. The percentage of ASIR-V represents the amount of iterative reconstruction, from 0% (filtered back projection only) to 100% iterative reconstruction, which modifies image noise and texture. When designing our study, ASIR-V was not yet studied for chest CT. The CT vendor engineers suggested an empirical percentage between 40 up to 100%, depending on radiologist practice and preferences. We decided to test percentages of iterative reconstruction of 50% and 100%. The LD CT images are reconstructed with 50% ASIR-V (LD) and the ULD CT images with 50% (ULD50) and 100% (ULD100) ASIR-V.

The statistical analyses will be performed twice: with ULD50 and ULD100.

Concerning the additional radiation for included patients, our ULD CT protocol has an expected effective dose between 0.10 and 0.20 mSv, which is about 6 to 20 times lower than the LD protocol (which is the usual dose in our institution for this indication), similar to a 2-views CXR, and to 30 days of natural radiation (21). Moreover, total dose of the entire exam (around 1.1 to 3 mSv) is lower than French diagnostic reference level of 6.65mSv.

Recruitment and intervention

Patients included in the study are those referred for a diagnostic chest CT without contrast media injection. On the day of the CT scan, a radiologist checks the eligibility criteria for the study, and informs the patient who signs a participation consent form if he accepts to join the study. The radiologist then collects the following parameters: height, weight, history of oncology, cardio-respiratory pathology and exposure to smoking. The patient then undergoes the standard diagnostic LD CT acquisition followed by the ULD acquisition. If, however, the dose of the LD acquisition is greater than 6.65mSv, the ULD acquisition is not performed and the patient is excluded from the data analysis. The patient's participation in the study is completed once he leaves the examination room.

The CT images of the LD acquisition are analysed by the radiologist who gives his medical report for the patient's medical management. If the number of nodules ≥ 4 mm identified on this acquisition is ≥ 6 in one lung, the patient will be excluded from the data analysis because the analysis of the outcomes will be too complicated to implement.

Patient and Public Involvement

Patients or public were not directly involved in the development of the research question. However, lowering the radiation dose is a rising concern for the patients and for public health. Patients were also not directly involved in the design, the recruitment and the conduct of this study.

As a regular medical care, the report of the diagnostic LD CT is sent to the prescribing physician, and to the patients at their request. According to French law, patients will be informed of the global results of the study at their request.

Blind reading of outcomes

For LD, ULD50 and ULD100 reconstructions, 2 radiologists will independently read all the radiological parameters. In order to limit the number of exams assessed by each reader, 4

radiologists split into 2 pairs will participate in the blind reading. Each pair of radiologists (1 junior and 1 senior radiologist) reads the three sets of images for the same patient in a random order. The term “blind” means that radiologists have neither knowledge of the patient's identity nor access to the results of diagnostic reading. To avoid patient identification, CT acquisitions are anonymized by deleting in the DICOM fields: the name, age and date of birth of the patient; the date and time of the examination and the name of the referring radiologist for the diagnosis. Each patient reconstruction is identified by a random number that differs for each of the two readers. Radiologists never read two series of the same patient consecutively. Anonymized exams are periodically transmitted to a pair with at least 15 LD, 15 ULD50 and 15 ULD100 reconstructions. The three patient reconstructions are not necessarily given the same day to both radiologists. In addition, the order of presentation is not identical for the two radiologists. The reading is performed on a diagnostic console (IMPAX software, 6.5.5.3502) (Agfa, Belgium) using Barco MDNC-3121 monitors (Barco, Courtrai, Belgium) and includes mediastinal and parenchymal filter reconstructions for each acquisition. The radiologist is free to adapt the level and width of the window to its reading practice (initial parenchymal window defined by a width of 1500UH and a level of -600UH), and to perform multiplanar reconstructions in the different plans of space. The reading also includes the additional MIP reconstruction for each acquisition, in order to sensitize the detection of nodules (22) (this type of reading from MIP series is performed in clinical routine). Radiologists identify nodules of longer diameter $\geq 4\text{mm}$ by locating them with the slice number and the lobe. It is known that each lung has three lobes (right upper lobe, middle lobe, right lower lobe, culmen, lingula, and left lower lobe). Each radiologist completes a reading grid for each reconstruction. The completed grids are given to a Clinical Research Assistant for data entry and identification of discrepancies in identification of nodules between the two radiologists. We consider that a nodule is the same between the two readers if:

1
2 300 • it is located in the same lobe
3
4 301 • the slice number is identical at ± 5 slices (a nodule will be visible on several successive
5
6 302 slices)
7
8 303 • the longest diameter of nodule is the same at ± 2 mm (23)
9
10 304 If these criteria are not respected or if a radiologist identifies one or more nodules in addition to or
11
12 305 less than the second radiologist, a consensus with a third CHUGA senior thoracic radiologist with
13
14 306 27 years of experience is obtained. This third radiologist is not part of the reading pairs. The
15
16 307 consensus is made from anonymized reconstructions and the reconstructions of the same patient are
17
18 308 not processed successively.
19
20
21 309 **Data monitoring**
22
23 310 All data is monitored by Grenoble-Alpes University Hospital (trial sponsor), in order to verify that
24
25 311 for every patient enrolled there is a signed consent form and that the inclusion and exclusion criteria
26
27 312 are respected. In addition all data collected in the case report form of every enrolled patient are
28
29 313 verified.
30
31
32 314 **Sample size**
33
34 315 With a 90% power, to have a sensitivity of detection of nodules with the ULD CT to 90% with a
35
36 316 confidence interval to $\pm 10\%$, it would be necessary to analyze 124 nodules. According to a
37
38 317 retrospective analysis of patients with indication of pulmonary nodule CT made at CHUGA, out of
39
40 318 420 patients per year with this indication, 210 present pulmonary nodules with a total of about 400
41
42 319 nodules. It should therefore include about 140 patients to have 124 nodules to be analyzed.
43
44 320 Considering a 5% potential loss to follow-up or withdrawal of consent, the actual number of
45
46 321 subjects to include is 147 in total. To this are added three potential patients who could be
47
48 322 secondarily excluded from the study for a number of nodules ≥ 6 in one of the lungs. The total
49
50 323 number of patients to include is 150. The sample size calculations were carried out using R software
51
52 324 version 3.1.0 (library MKmisc, function power.diagnostic.test) (24, 25, 26).
53
54
55
56 325

Statistical analysis

In this non-randomized study where each patient is his own control, the threshold $p < 0.05$ will be taken into account to define the significance of the statistical tests. Analyses will be carried out in accordance with good statistical analysis practices after freezing of the database and will be carried out with the software R (version $\geq 3.1.0$). If the missing data rate of the primary criterion is between 5% and 20%, the missing data for this criterion will be replaced. The replacement of the missing data will be done, either according to a worst-case analysis strategy, by disfavoring the assumption that one seeks to demonstrate, either by a multiple imputation method. In case of multiple imputations, five imputations will be made, using a linear regression model taking into account the following variables: age, sex, BMI, smoking habit.

The normality of the quantitative parameters will be determined by the Shapiro-Wilks test or by graphical verification of the symmetry of the distribution. When the normality of the distribution of such a parameter has been demonstrated, it will be described by its mean and its standard deviation. Otherwise it will be described by its median, the 25th and the 75th percentile. The qualitative parameters will be expressed in number and percentage.

For the main objective, the sensitivity of the ULD CT (compared to the LD CT) for the detection of nodules will be calculated and accompanied by a 95% confidence interval. For secondary objective 1, the number of TP, FP, TN, FN, PPV, NPV and Sp of the ULD CT (compared to LD CT) will be calculated. For secondary objectives 2, 5, 6 and 7, the concordance of the qualitative variables will be evaluated using the kappa coefficient. The concordance of the quantitative variables will be evaluated using Lin's concordance coefficient. For each coefficient, the 95% confidence interval will be given. For secondary objective 3, inter-observer reproducibility for qualitative variables will be evaluated using the kappa coefficient. It will be evaluated, for the quantitative variables, using the ICC (intra class coefficient). For each coefficient, the 95% confidence interval will be given. For secondary objective 4, a logistic regression model will be implemented. The variable to be explained will be the result of detecting each nodule in ULD CT compared to the LD CT (0 = good

detection / 1 = bad detection). The explanatory variables will be the age, sex and BMI of the patient, the location (lobe) and the size of the nodule. The size of the nodule can be used as a qualitative variable (<5mm, 5-10mm,> 10mm). An interim analysis including the analysis of the primary endpoint will be performed after inclusion of the first 50 patients. This interim analysis will aim to: decide whether to continue or stop the study for futility and readjust the number of patients if necessary (if the characteristics of the patients included do not correspond to those initially planned (too many patients without nodules ≥ 4 mm)). In order to maintain an overall threshold of 5% in the final analysis, the interim analysis will be carried out with a threshold of 0.1%. The results of the interim analysis will be taken into account by the steering committee to propose modifications to the analysis plan. For this interim analysis, data from the confrontation between the two radiologists will be used.

Limitations

First limitation of our protocol is that we do not have a true screening population because there is no organized lung cancer screening program in our country yet. Therefore, our study population corresponds to patients routinely referred for lung nodule checkup or follow up instead of a risk-factor based population. Another limitation is that ULD CT is easily recognizable as the image noise is increased as compared to LD CT, as well as ULD 50 and ULD 100 are possible to distinguish for an experienced radiologist. As a consequence, readers were not blinded for these, but for patient name, sex, age, clinical status, and CT report. Recall bias is limited by a randomized order of presentation and cutting into several reading sessions. Although we wanted to have a “western population”, we decided not to include obese patients with a BMI>35, because ULD CT are of poorer quality, due to the need of more radiation-exposure to produce acceptable images. Vardhanabhuti and al. recently found a loss of nodule detection with

iterative reconstructed CT scanners at an effective dose of 0.14 ± 0.01 mSv for obese patients with BMI > 38 (27).

We decided to test percentage of 50 and 100% of ASIR-V. Tang and al. tested ASIR-V from 10 to 100% in non-enhanced chest and showed ASIR-V has greater potential in reducing image noise and artifacts and maintaining image sharpness when compared to ASIR, and 60% ASIR-V had the highest image quality combining both the objective and subjective evaluation of images (28). This finding, although occurring after the design of our study is close to our chosen 50% level of ASIR-V.

FUNDING

This trial is funded by the Delegation to Clinical Research and Innovation (DRCI) of Grenoble-Alpes University Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

AUTHOR CONTRIBUTIONS

M. Ludwig is the corresponding author and contributed to the conception of the study, to the inclusion of patients, to the blind reading of outcomes and to the drafting of the manuscript.

E. Chipon contributed to the conception of the study, to the drafting of the manuscript, and is responsible for data management and its integrity.

J. Cohen contributed to the conception of the study, to the inclusion of patients, to the blind reading of outcomes and to the revision of the manuscript.

E. Reymond contributed to the inclusion of patients, to the blind reading of outcomes and to the revision of the manuscript.

M. Medici contributed to the design and application of statistical analysis, and to the drafting of the manuscript.

A. Cole contributed to the blind reading of outcomes and to the revision of the manuscript.

1
2 404 A. Moreau Gaudry contributed to the conception of the study and to the revision of the manuscript.
3
4 405 G R Ferretti is the principal investigator of the study and contributed to the conception of the work,
5
6 406 to the inclusion of patients, to the blind consensus of outcomes and to the revision of the
7
8 407 manuscript.
9
10 408 All authors approved the final manuscript and agreed to be accountable for all aspects of the work.
11
12 409

13
14 410 **COMPETING INTERESTS**

15
16
17 411 The authors declare that they have no competing interests
18
19 412

20
21 413 **CONSENT FOR PUBLICATION**

22
23 414 Not applicable
24
25 415

26
27 416 **ETHICS AND DISSEMINATION**

28
29 417 This trial is registered on the ClinicalTrials.gov database (reference NCT03305978) (see
30
31 418 supplementary file “trial registration data set”), and was approved by the relevant ethical committee
32
33 419 (Comité de Protection des Personnes, CPP sud-est VI, France, 07/07/2017, CPP Reference:
34
35 420 AU1342). The Protocol version is N°1.0- Date: May 4th 2017
36
37 421

38
39 422 All patients sign a consent form before being enrolled in the trial, in accordance with the
40
41 423 Declaration of Helsinki II.

42
43 424 Once the statistical report is finalized, we plan to publish our results in an international scientific
44
45 425 journal and present them in national and international congresses.
46
47 426

48
49
50 427 **DATA STATEMENT**

51
52 428 Legal restrictions (French personal data laws) prohibit the authors from making the minimal data set
53
54 429 publicly available. These data are available upon request.
55
56
57
58
59
60

ACKNOWLEDGEMENTS

The authors thank Alexandre Rey and Pierre Pittet for their help to collect and prepare data, Tarek Ittobane for data monitoring, Dr A. Jankowski for the inclusion of patients, and Laura Cotarla for English proofreading.

REFERENCES

1. Globocan : Lung Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx)
2. National Lung Screening Trial Research Team, Denise R. Aberle, Amanda M. Adams, Christine D. Berg, William C. Black, Jonathan D. Clapp, Richard M. Fagerstrom, et al. “Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening.” *The New England Journal of Medicine* 365, no. 5 (August 4, 2011): 395–409. doi:10.1056/NEJMoa1102873
3. Yousaf-Khan U, van der Aalst C, de Jong PA, et al. “Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval.” *Thorax* 2017;72:48-56. 10.1136/thoraxjnl-2016-208655
4. Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation and National Research Council. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, D.C: The National Academies Press; 2006
5. Kubo T, Ohno Y, Seo JB, Yamashiro T, Kalender WA, Lee CH, et al. “Securing safe and informative thoracic CT examinations-Progress of radiation dose reduction techniques”. *Eur J Radiol.* 2017 Jan;86:313–9.
6. Kim, Yookyung, Yoon Kyung Kim, Bo Eun Lee, SeokJeong Lee, YonJuRyu, Jin Hwa Lee, and Jung Hyun Chang. “Ultra-Low-Dose CT of the Thorax Using Iterative Reconstruction:

Evaluation of Image Quality and Radiation Dose Reduction.” *AJR. American Journal of Roentgenology* 204, no. 6 (June 2015): 1197–1202. doi:10.2214/AJR.14.13629.

7. Vardhanabhuti, Varut, Robert J. Loader, Grant R. Mitchell, Richard D. Riordan, and Carl A. Roobottom. “Image Quality Assessment of Standard- and Low-Dose Chest CT Using Filtered Back Projection, Adaptive Statistical Iterative Reconstruction, and Novel Model-Based Iterative Reconstruction Algorithms.” *AJR. American Journal of Roentgenology* 200, no. 3 (March 2013): 545–52. doi:10.2214/AJR.12.9424.

8. Ichikawa, Yasutaka, Kakuya Kitagawa, Naoki Nagasawa, Shuichi Murashima, and Hajime Sakuma. “CT of the Chest with Model-Based, Fully Iterative Reconstruction: Comparison with Adaptive Statistical Iterative Reconstruction.” *BMC Medical Imaging* 13 (2013): 27. doi:10.1186/1471-2342-13-27.

9. Padole, Atul, Sarabjeet Singh, Jeanne B. Ackman, Carol Wu, Synho Do, Sarvenaz Pourjabbar, Ranish Deedar Ali Khawaja, et al. “Submillisievert Chest CT with Filtered Back Projection and Iterative Reconstruction Techniques.” *AJR. American Journal of Roentgenology* 203, no. 4 (October 2014): 772–81. doi:10.2214/AJR.13.12312.

10. Montet, Xavier, Anne-Lise Hachulla, Angeliki Neroladaki, Frederic Lador, Thierry Rochat, Diomidis Botsikas, and Christoph D. Becker. “Image Quality of Low mA CT Pulmonary Angiography Reconstructed with Model Based Iterative Reconstruction versus Standard CT Pulmonary Angiography Reconstructed with Filtered Back Projection: An Equivalency Trial.” *EuropeanRadiology* 25, no. 6 (June 2015): 1665–71. doi:10.1007/s00330-014-3563-5.

11. Yoon, Hyun Jung, Myung Jin Chung, Hye Sun Hwang, Jung Won Moon, and Kyung Soo Lee. “Adaptive Statistical Iterative Reconstruction-Applied Ultra-Low-Dose CT with Radiography-Comparable Radiation Dose: Usefulness for Lung Nodule Detection.” *Korean Journal of Radiology* 16, no. 5 (October 2015): 1132–41. doi:10.3348/kjr.2015.16.5.1132


12. Sui, Xin, Felix G. Meinel, Wei Song, Xiaoli Xu, Zixing Wang, Yuyan Wang, Zhengyu Jin, Jiahong Chen, Rozemarijn Vliegenthart, and U. Joseph Schoepf. "Detection and Size Measurements of Pulmonary Nodules in Ultra-Low-Dose CT with Iterative Reconstruction Compared to Low Dose CT." *European Journal of Radiology* 85, no. 3 (March 2016): 564–70. doi:10.1016/j.ejrad.2015.12.013
13. Nagatani Y, Takahashi M, Murata K, Ikeda M, Yamashiro T, Miyara T, Koyama H, Koyama M, Sato Y, Moriya H, et al "Lung nodule detection performance in five observers on computed tomography (CT) with adaptive iterative dose reduction using three-dimensional processing (AIDR 3D) in a Japanese multicenter study: Comparison between ultra-low-dose CT and low-dose CT by receiver-operating characteristic analysis". *Eur J Radiol.* 2015 Jul; 84(7):1401-12. Epub 2015 Apr 2
14. Huber, Adrian, Julia Landau, Lukas Ebner, Yanik Bütikofer, Lars Leidolt, Barbara Brela, Michelle May, Johannes Heverhagen, and Andreas Christe. "Performance of Ultralow-Dose CT with Iterative Reconstruction in Lung Cancer Screening: Limiting Radiation Exposure to the Equivalent of Conventional Chest X-Ray Imaging." *European Radiology*, January 26, 2016. doi:10.1007/s00330-015-4192-3
15. Messerli M, Kluckert T, Knitel M, Wälti S, Desbiolles L, Rengier F, et al. "Ultralow dose CT for pulmonary nodule detection with chest x-ray equivalent dose - a prospective intra-individual comparative study". *EurRadiol.* 2017 Aug;27(8):3290–9.
16. Neroladaki, Angeliki, Diomidis Botsikas, Sana Boudabbous, Christoph D. Becker, and Xavier Montet. "Computed Tomography of the Chest with Model-Based Iterative Reconstruction Using a Radiation Exposure Similar to Chest X-Ray Examination: Preliminary Observations." *European Radiology* 23, no. 2 (February 2013): 360–66. doi:10.1007/s00330-012-2627-7.
17. De Marco P, Origgi D. "New adaptive statistical iterative reconstruction ASiR-V: Assessment of noise performance in comparison to ASiR". *J Appl Clin Med Phys.* 2018

1
2 506 Mar;19(2):275-286. doi: 10.1002/acm2.12253. Epub 2018 Jan 24. PubMed PMID:
3
4 507 29363260; PubMed Central PMCID: PMC5849834
5
6 508 18. Gierada DS, Pinsky P, Nath H, Chiles C, Duan F, Aberle DR. "Projected outcomes using
7
8 509 different nodule sizes to define a positive CT lung cancer screening examination". J Natl
9
10 510 Cancer Inst. 2014;106:dju284.
11
12 511 19. Ahn MI, Gleeson TG, Chan IH et-al. "Perifissural nodules seen at CT screening for lung
13
14 512 cancer". Radiology. 2010;254 (3): 949-56. doi:10.1148/radiol.09090031
15
16 513 20. Task Group on Control of Radiation Dose in Computed Tomography. "Managing Patient
17
18 514 Dose in Computed Tomography. A Report of the International Commission on Radiological
19
20 515 Protection." *Annals of the ICRP* 30, no. 4 (2000): 7-45
21
22 516 21. Exposition de la population française aux rayonnements ionisants liée aux actes de
23
24 517 diagnostic médical en 2012. Rapport IRSN PRP-HOM N°2014-6
25
26 518 22. Jankowski, A., T. Martinelli, J. F. Timsit, C. Brambilla, F. Thony, M. Coulomb, and G.
27
28 519 Ferretti. "Pulmonary Nodule Detection on MDCT Images: Evaluation of Diagnostic
29
30 520 Performance Using Thin Axial Images, Maximum Intensity Projections, and Computer-
31
32 521 Assisted Detection." *European Radiology* 17, no. 12 (December 2007): 3148-56.
33
34 522 doi:10.1007/s00330-007-0727-6.
35
36 523 23. Revel MP, Bissery A, Bienvenu M, Aycard L, Lefort C, Fria G. Are two-dimensional CT
37
38 524 measurements of small noncalcified pulmonary nodules reliable? *Radiology*. 2004
39
40 525 May;231(2):453-8. PubMed PMID: 15128990.
41
42 526 24. A. Flahault, M. Cadilhac, and G. Thomas (2005). Sample size calculation should be
43
44 527 performed for design accuracy in diagnostic test studies. *Journal of*
45
46 528 *ClinicalEpidemiology*, 58(8):859-862.
47
48 529 25. H. Chu and S.R. Cole (2007). Sample size calculation using exact methods in diagnostic test
49
50 530 studies. *Journal of ClinicalEpidemiology*, 60(11):1201-1202.
51
52
53
54
55
56
57
58
59
60

26. M.R. Chernick and C.Y. Liu (2002). The saw-toothed behavior of power versus sample size and software solutions: single binomial proportion using exact methods. *Am Stat*, 56:149-155.
27. Vardhanabhuti V, Pang CL, Tenant S, Taylor J, Hyde C, Roobottom C. "Prospective intra-individual comparison of standard dose versus reduced-dose thoracic CT using hybrid and pure iterative reconstruction in a follow-up cohort of pulmonary nodules-Effect of detectability of pulmonary nodules with lowering dose based on nodule size, type and body mass index". *Eur J Radiol*. 2017 Jun;91:130-141. doi: 10.1016/j.ejrad.2017.04.006
28. Tang H, Yu N, Jia Y, Yu Y, Duan H, Han D, et al. "Assessment of noise reduction potential and image quality improvement of a new generation adaptive statistical iterative reconstruction (ASIR-V) in chest CT". *Br J Radiol*. 2018 Jan;91(1081):20170521

FIGURE 1 legend:

Study Flow chart. ASIR-V[®], adaptive statistical iterative reconstruction-Véo (GE medical Healthcare, Milwaukee, WI, USA); CT, computed tomography; LD, low dose; LD50, low dose CT with 50% ASIR-V reconstruction; ULD, ultra-low dose; ULD50, ultra-low dose CT with 50% ASIR-V reconstruction, ULD 100, ultra-low dose CT with 100% ASIR-V reconstruction



Study Flow chart. ASIR-V ®, adaptive statistical iterative reconstruction-Véo (GE medical Healthcare, Milwaukee, WI, USA); CT, computed tomography; LD, low dose; LD50, low dose CT with 50% ASIR-V reconstruction; ULD, ultra-low dose; ULD50, ultra-low dose CT with 50% ASIR-V reconstruction, ULD 100, ultra-low dose CT with 100% ASIR-V reconstruction.

210x297mm (300 x 300 DPI)

Trial registration data set :

Primary registry and trial identifying number	ClinicalTrials.gov NCT03305978
Date of registration in primary registry	September 26, 2017
Secondary identifying numbers	38RC17.132
Source(s) of monetary or material support	University Hospital, Grenoble
Primary sponsor	University Hospital, Grenoble
Secondary sponsor(s)	French Thoracic Imaging Society
Contact for public queries	Emilie CHIPON, PhD, +33476767313, echipon@chu-grenoble.fr
Contact for scientific queries	Gilbert FERRETTI, MD PhD, +3376767313, gferretti@chu-grenoble.fr
Public title	Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan.
Scientific title	Detection of Pulmonary Nodules: Comparison of Ultra-low-dose Chest CT (Approaching a Two Views Chest X-ray Radiation) and Standard Low Dose CT. A Monocentric, Prospective, Non-randomized, Comparative, Open-label Study With Blind Reading of the Judgment Criteria
Country of recruitment	France
Health condition(s) or problem(s) studied	Lung cancer screening, radiation exposure
Intervention(s)	<p><u>Device: Ultra low dose chest CT</u> An additional ultra low dose CT row is performed for every subject besides standard diagnostic low dose chest CT. Other Name: Revolution CT (GE Healthcare) 442507CN0, equipped with ASIR V</p> <p><u>Device: Low dose chest CT</u> standard diagnostic low dose chest CT Other Name: Revolution CT (GE Healthcare)</p>
Key inclusion and exclusion criteria	<p>Ages eligible for study: ≥ 18 years Sexes eligible for study: both Accepts healthy volunteers: no</p> <p><u>Inclusion criteria :</u> Patients referred for non enhanced chest CT for following indications :</p> <ul style="list-style-type: none"> - lung nodule search or control - nodular abnormality on chest X ray - statement of COPD or emphysema - asbestos exposure - nodule localization before radio frequency ablation - assessment of disease extent of an extra thoracic cancer (in case of iodinated intravenous contrast agent contraindication) - statement before extrathoracic transplantation (in case of iodinated intravenous contrast agent contraindication) <p>Affiliated with the french social security Who signed consent</p> <p><u>Exclusion criteria :</u> Inability to lie down and stay still during the examination Inability to hold breath more than 5 seconds Pneumonia in the last 3 months Body mass index more than 35kg/m² exclusion period of another interventionnal study</p>

	referred for articles L1121-5 to L1121-8 of french public health code Pregnant or breastfeeding women
Study type	<p>Interventional</p> <p><u>Allocation</u>: Non-Randomized</p> <p><u>Intervention Model</u>: Sequential Assignment</p> <p><u>Intervention Model Description</u>: Major Patient Addressed for Thoracic CT without Injection of Contrast</p> <p><u>Masking</u>: Single (Outcomes Assessor)</p> <p><u>Masking Description</u>: blinding evaluation of criteria</p> <p><u>Primary purpose</u>: diagnostic</p>
Date of first enrolment	October 3, 2017
Target sample size	150
Recruitment status	Recruiting
Primary outcome(s)	<p>Ultra low dose CT lung nodule detection sensibility [Time Frame: 22 months]</p> <p>Detection rate (%) of ≥ 4mm lung nodules in ultra low dose chest CT versus standard low</p>
Key secondary outcomes	<ul style="list-style-type: none"> - Ultra low dose CT diagnostic performances of lung nodule detection [Time Frame: 22 months] :true positives, false positives, true negatives, false negatives, positive predictive value, negative predictive value, specificity, of ≥ 4mm lung nodules detection within ultra low dose chest CT versus standard low dose chest CT - Concordance of ≥ 4mm lung nodules characteristics between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : comparison of size, density, type (true nodule or intrapulmonary ganglion) of ≥ 4mm lung nodule between ultra low dose and standard low dose chest CT - Ultra low dose CT inter-observer reproducibility [Time Frame: 22 months] : inter observer reproducibility for size, density and type of ≥ 4mm lung nodule detected in ultra low dose CT - Influence of subjects characteristics, nodule location, and nodule size on detection between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : analysis of subjects characteristics (age, gender, body mass index), ≥ 4mm nodule location, and ≥ 4 mm nodule size on detection between ultra low dose and standard low dose chest CT - Concordance of emphysema characteristics between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : comparison of emphysema detection, type (centrilobular, paraseptal, panlobular, bullous) and distribution between ultra low dose and standard low dose chest CT - Concordance of coronary calcification detection and quantification between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : Comparison of Weston scores between ultra low dose and standard low dose chest CT - Concordance of bronchial abnormalities evaluation between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : comparison of detection of bronchial thickening or dilatation between ultra low dose and standard low dose chest CT
Ethics Review	approved by the relevant ethical committee (Comité de Protection des Personnes, CPP Sud-Est VI, France, CPP Reference: AU1342), on July 7, 2017

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	17
Protocol version	#3	Date and version identifier	18
Funding	#4	Sources and types of financial, material, and other support	16
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1;16
Roles and responsibilities:	#5b	Name and contact information for the trial sponsor	2

1	sponsor contact			
2	information			
3				
4	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	16
5	responsibilities:		collection, management, analysis, and interpretation of	
6	sponsor and funder		data; writing of the report; and the decision to submit the	
7			report for publication, including whether they will have	
8			ultimate authority over any of these activities	
9				
10				
11				
12	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	n/a
13	responsibilities:		centre, steering committee, endpoint adjudication	
14	committees		committee, data management team, and other individuals or	
15			groups overseeing the trial, if applicable (see Item 21a for	
16			data monitoring committee)	
17				
18				
19				
20	Background and	#6a	Description of research question and justification for	5
21	rationale		undertaking the trial, including summary of relevant studies	
22			(published and unpublished) examining benefits and harms	
23			for each intervention	
24				
25				
26				
27	Background and	#6b	Explanation for choice of comparators	6
28	rationale: choice of			
29	comparators			
30				
31				
32	Objectives	#7	Specific objectives or hypotheses	7
33				
34				
35	Trial design	#8	Description of trial design including type of trial (eg, parallel	7
36			group, crossover, factorial, single group), allocation ratio,	
37			and framework (eg, superiority, equivalence, non-inferiority,	
38			exploratory)	
39				
40				
41				
42	Study setting	#9	Description of study settings (eg, community clinic,	7
43			academic hospital) and list of countries where data will be	
44			collected. Reference to where list of study sites can be	
45			obtained	
46				
47				
48	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	8
49			eligibility criteria for study centres and individuals who will	
50			perform the interventions (eg, surgeons, psychotherapists)	
51				
52				
53				
54	Interventions:	#11a	Interventions for each group with sufficient detail to allow	10
55	description		replication, including how and when they will be	
56			administered	
57				
58				
59				
60				

Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	11
Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	n/a
Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	n/a
Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	8
Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	7
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	13
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	11
Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	n/a
Allocation concealment	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed	n/a

1	mechanism		envelopes), describing any steps to conceal the sequence	
2			until interventions are assigned	
3				
4	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	n/a
5	implementation		participants, and who will assign participants to	
6			interventions	
7				
8				
9	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	11
10			trial participants, care providers, outcome assessors, data	
11			analysts), and how	
12				
13				
14	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	n/a
15	emergency		permissible, and procedure for revealing a participant's	
16	unblinding		allocated intervention during the trial	
17				
18				
19				
20	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	12
21			and other trial data, including any related processes to	
22			promote data quality (eg, duplicate measurements, training	
23			of assessors) and a description of study instruments (eg,	
24			questionnaires, laboratory tests) along with their reliability	
25			and validity, if known. Reference to where data collection	
26			forms can be found, if not in the protocol	
27				
28				
29				
30				
31	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	n/a
32	retention		up, including list of any outcome data to be collected for	
33			participants who discontinue or deviate from intervention	
34			protocols	
35				
36				
37				
38	Data management	#19	Plans for data entry, coding, security, and storage, including	13
39			any related processes to promote data quality (eg, double	
40			data entry; range checks for data values). Reference to	
41			where details of data management procedures can be	
42			found, if not in the protocol	
43				
44				
45				
46	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	13
47			outcomes. Reference to where other details of the statistical	
48			analysis plan can be found, if not in the protocol	
49				
50				
51				
52	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	14
53	analyses		adjusted analyses)	
54				
55	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	13
56	population and		adherence (eg, as randomised analysis), and any statistical	
57	missing data		methods to handle missing data (eg, multiple imputation)	
58				
59				
60				

1	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	13
2	formal committee		of its role and reporting structure; statement of whether it is	
3			independent from the sponsor and competing interests; and	
4			reference to where further details about its charter can be	
5			found, if not in the protocol. Alternatively, an explanation of	
6			why a DMC is not needed	
7				
8				
9				
10				
11	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	14
12	interim analysis		including who will have access to these interim results and	
13			make the final decision to terminate the trial	
14				
15				
16	Harms	#22	Plans for collecting, assessing, reporting, and managing	n/a
17			solicited and spontaneously reported adverse events and	
18			other unintended effects of trial interventions or trial conduct	
19				
20				
21	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	n/a
22			and whether the process will be independent from	
23			investigators and the sponsor	
24				
25				
26				
27	Research ethics	#24	Plans for seeking research ethics committee / institutional	16
28	approval		review board (REC / IRB) approval	
29				
30				
31	Protocol	#25	Plans for communicating important protocol modifications	n/a
32	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
33			relevant parties (eg, investigators, REC / IRBs, trial	
34			participants, trial registries, journals, regulators)	
35				
36				
37	Consent or assent	#26a	Who will obtain informed consent or assent from potential	16
38			trial participants or authorised surrogates, and how (see	
39			Item 32)	
40				
41				
42				
43	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
44	ancillary studies		participant data and biological specimens in ancillary	
45			studies, if applicable	
46				
47				
48	Confidentiality	#27	How personal information about potential and enrolled	n/a
49			participants will be collected, shared, and maintained in	
50			order to protect confidentiality before, during, and after the	
51			trial	
52				
53				
54				
55	Declaration of	#28	Financial and other competing interests for principal	16
56	interests		investigators for the overall trial and each study site	
57				
58				
59	Data access	#29	Statement of who will have access to the final trial dataset,	19
60				

			and disclosure of contractual agreements that limit such access for investigators	
	Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
	Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	16
	Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
	Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
	Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	n/a
	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a

The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 23. July 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Detection of pulmonary nodules: a clinical study protocol to compare ultra-low dose chest CT and standard low-dose CT using ASIR-V.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025661.R1
Article Type:	Protocol
Date Submitted by the Author:	03-Dec-2018
Complete List of Authors:	Ludwig, Marie; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine Chipon, Emilie; INSERM, CIC 1406; Centre Hospitalier Universitaire Grenoble Alpes, pôle recherche Cohen, Julien; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine Reymond, Emilie; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie Medici, Maud; INSERM, CIC 1406; Centre Hospitalier Universitaire Grenoble Alpes, pôle recherche Cole, Anthony; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine Moreau Gaudry, Alexandre; INSERM, CIC 1406; Centre Hospitalier Universitaire Grenoble Alpes, pôle recherche Ferretti, Gilbert; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine
Primary Subject Heading:	Radiology and imaging
Secondary Subject Heading:	Oncology, Respiratory medicine, Smoking and tobacco
Keywords:	low dose computed tomography, ultra low dose computed tomography, pulmonary nodule, lung cancer screening, iterative reconstruction

SCHOLARONE™
Manuscripts

1 Detection of pulmonary nodules: a clinical study protocol to compare ultra-low
2 dose chest CT and standard low-dose CT using ASIR-V.

3 M Ludwig, E Chipon, J Cohen, E Reymond, M Medici, A. Colé, A. Moreau-Gaudry, G R Ferretti

5 **Corresponding author:**

6 *Marie Ludwig*

7 Service de radiologie diagnostique et thérapeutique

8 CHU Grenoble Alpes

9 CS 10217

10 38043 Grenoble CEDEX 9

11 France

12 mludwig@chu-grenoble.fr

13 +33 476769290

15 *Affiliations E. Chipon /M.Medici*

16 INSERM, CIC 1406, F-38000 Grenoble, France

17 Université Grenoble-Alpes, CIC 1406, F-38000 Grenoble, France

18 CHU Grenoble-Alpes, Pôle Recherche, F-38000 Grenoble, France

19 *Affiliations A. Moreau-Gaudry*

20 Université Grenoble-Alpes, CNRS, Grenoble INP, TIMC-IMAG, F-38000 Grenoble, France

21 INSERM, CIC 1406, F-38000 Grenoble, France

22 CHU Grenoble-Alpes, Pôle Recherche, F-38000 Grenoble, France

23 CHU Grenoble-Alpes, Pôle Santé Publique, F-38000 Grenoble, France

24 *Affiliations G.R. Ferretti, M Ludwig, J Cohen, E Reymond, A.Cole*

25 Université Grenoble-Alpes, F-38000 Grenoble, France

Service de radiologie diagnostique et thérapeutique, CHU Grenoble Alpes, CS 10217, 38043
Grenoble CEDEX 9, France

28

Sponsor:

Delegation to Clinical Research and Innovation (DRCI) of Grenoble-Alpes University Hospital
CHU Grenoble-Alpes, Pôle Recherche, F-38000 Grenoble, France
+33476767575

33

34

35

KEYWORDS

Low dose computed tomography, Ultra low-dose computed tomography, pulmonary nodule, Lung
cancer screening, iterative reconstruction

39

40

Word count, excluding title page, abstract, article summary, references, figures, tables, and
acknowledgements : 4055

43

44

45

46

47

1
2 48 **ABSTRACT**

3
4 49 Introduction:

5
6 50 Lung cancer screening in individuals at risk has been recommended by various scientific
7
8 51 institutions. One of the main concerns for CT screening is repeated radiation exposure, with the risk
9
10 52 of inducing malignancies in healthy individuals. Therefore, lowering the radiation dose is one of the
11
12 53 main objectives for radiologists. The aim of this study is to demonstrate that an ultra-low dose
13
14 54 (ULD) chest CT protocol, using recently introduced hybrid iterative reconstruction (ASiR-V, GE
15
16 55 medical Healthcare, Milwaukee, WI, USA), is as performant as a standard “low dose” (LD) CT to
17
18 56 detect non calcified lung nodules $\geq 4\text{mm}$.
19

20
21
22 57 Methods and analysis:

23
24 58 The total number of patients to include is 150. Those are referred for non-enhanced chest CT for
25
26 59 detection or follow-up of lung nodule and will undergo an additional unenhanced ULD CT
27
28 60 acquisition, the dose of which is on average 10 times lower than the conventional LD acquisition.
29
30 61 Total dose of the entire exam (LD + ULD) is lower than the French diagnostic reference level for a
31
32 62 chest CT (6.65 milliSievert). ULD CT images will be reconstructed with 50% and 100% ASiR-V,
33
34 63 and LD CT with 50%. The 3 sets of images will be read in random order by two pair of radiologists,
35
36 64 in a blind test, where patient identification and study outcomes are concealed. Detection rate
37
38 65 (sensitivity) is the primary outcome. Secondary outcomes will include concordance of nodule
39
40 66 characteristics; inter-observer reproducibility; influence of subjects’ characteristics, nodule location,
41
42 67 and nodule size; and concordance of emphysema, coronary calcifications evaluated by visual
43
44 68 scoring and bronchial alterations between LD and ULD CT. In case of discordance, a third
45
46 69 radiologist will arbitrate.
47

48
49
50 70 Ethics and dissemination:

51
52 71 The study was approved by the relevant ethical committee. Each study participant will sign an
53
54 72 informed consent form.
55

56
57 73 **Trial registration number:** *Clinicaltrials.gov* NCT03305978
58
59
60

1
2 74
3
4 75
5
6 76
7
8
9 77
10
11 78
12
13 79
14
15 80
16
17 81
18
19 82
20
21 83
22
23 84
24
25 85
26
27 86
28
29 87
30
31 88
32
33 89
34
35 90
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY:

STRENGTHS AND LIMITATIONS OF THIS STUDY

- We will evaluate the sensitivity of an ultra-low dose CT, delivering 10 times less radiation than conventional low-dose CT, to detect lung nodules, in a French population of 150 patients referred for lung nodule check-up or follow-up.
- We will use a recently introduced hybrid iterative reconstruction (ASiR-V) and different levels of ASiR-V will be assessed
- Nodules characteristics will be analyzed in particular the diagnosis of intrapulmonary lymph node, which is a benign lesion.
- Patients with morbid obesity (BMI>35) will not be included as image quality of ultra-low dose CT is not acceptable for those morphotypes.
- Readers will be aware of the type of CT acquisition (LD and ULD) and reconstruction, because they are easily recognizable due to the different level of image noise.

1
2 91 **INTRODUCTION**

3
4 92 Lung cancer is the deadliest cancer in the world (1), mainly due to the fact that it is often diagnosed
5
6 93 at advanced stages that are not surgically curable. The current challenge is therefore to detect lung
7
8
9 94 cancer at early asymptomatic stages. Risk factors such as smoking and occupational exposure
10
11 95 (mainly asbestos, silica, arsenic, chromium, iron, coal, ionising radiation) are well known and
12
13 96 enable to define the target population for such programs.

14
15
16 97 The National Lung Screening Trial (NLST) was the first study to show that a low dose (LD)
17
18 98 (average effective dose of 1.5mSv) computed tomography (CT) lung cancer screening reduced
19
20 99 specific death by 20% (95% CI, 6.8 to 26.7; P=0.004) as compared with chest X Ray (CXR)
21
22
23 100 screening (single-view posteroanterior) in actual or former smokers (>30 pack years) patients
24
25 101 between 55 and 74 years old (2).

26
27 102 Other lung cancer screening studies are still in progress in Europe, such as the NELSON study in
28
29
30 103 Belgium and the Netherlands, the results of which are expected to be reported soon (3)

31
32 104 However, the drawback of using LD CT at such doses (<1.5 millisievert (mSv)) is that even though
33
34 105 irradiating less than standard chest CT, the radiation exposure is still on average 10 times higher
35
36 106 than a 2 views CXR, and may be a risk for induced malignancies in itself. (4)

37
38
39 107 In this context, great efforts are currently being made by CT manufacturers to reduce the dose and
40
41 108 maintain diagnostic quality. Technologies such as automated exposure control, lower tube current
42
43 109 and iterative reconstruction (5), were recently introduced, enabling further dose decrease for chest
44
45
46 110 CTs, and the concept of “ultra-low dose (ULD) CT” (or submillisievert CT), which delivers a
47
48 111 radiation dose approaching that of 2 CXR views at the cost of a slight deterioration of the image
49
50 112 quality (6) . Among these technological advances, the most significant is probably the new iterative
51
52
53 113 reconstruction whether full iterative or hybrid. (7,8,9,10)

54
55 114 Promising results have been published for lung nodule detection with ULD CT (11,12,13).
56
57 115 However, these studies were conducted on Asian populations, which may have different
58
59 116 morphotypes compared to Caucasian populations.

Huber and al. performed a phantom study comparing standard, LD and ULD CT for detection of pulmonary nodules. When compared to standard CT, the detection rate was 95.5% for LD CT (1.76 mSv), and 93.3% for ULD CT (0.13mSv), increasing at 97.5% when adding computer aided diagnosis and maximal intensity projection (14).

Since we started to design our study protocol, Messerli and al. published a study including 202 patients referred for any clinically indicated chest CT. 91.2% nodules were detected using ULD CT (0.13 \pm 0.01mSv) as compared to LD CT (1.8 \pm 0.7 mSv). Sensitivity was significantly higher for larger nodule diameter, lower BMI patients, lower image noise and for solid and calcified nodules (15).

Neroladaki and al. showed the same number of detected nodules between an ULD acquisition (0.16 \pm 0.006mSv) with iterative reconstruction and a standard dose filtered back projection acquisition (11.2 \pm 2.7mSv), and more nodules detected with model based iterative reconstruction (MBIR) than adaptive statistical iterative reconstruction (ASIR) (16). MBIR is known to better minimize image noise compared to ASIR : Ichikawa and al found a significantly lower image noise with LD (1.6 \pm 0.8 mSv) MBIR CT (11.6 \pm 1.0 Hounsfield units (HU)) than with LD ASIR CT (21.1 \pm 2.6 HU, $p < 0.0005$), a slightly better image quality score for decreased lung attenuation lesion, and no difference in image quality scores for consolidation or mass, ground-glass attenuation, or reticular opacity with MBIR compared to ASIR LD CT (8). But MBIR may slightly deteriorate lesion margin (9), and significantly increases reconstruction time, taking more than 30 minutes, when patients lie less than 10 minutes in the machine. ASIR-V is the latest generation of hybrid iterative reconstruction (GE medical Healthcare, Milwaukee, WI). It combines ASIR and MBIR and enables a better noise reduction than ASIR, with a processing time of only few minutes, suitable to a routine chest CT session (17).

According to the ALARA (as low as reasonably achievable) principle, we hope to validate our ULD chest CT protocol (<0.2mSv), the dose of which is 10 times lower than a usual LD CT, as a

1
2 143 sensitive tool to detect lung nodules. Thus, this ULD CT acquisition could be generalized for lung
3
4 144 nodules detection and would consolidate the setup of lung cancer screening programs. Also, this
5
6 145 would allow the generalization of ULD protocols, for radiation sensitive populations (children and
7
8
9 146 young adults in particular).

10
11 147
12

13 **METHODS AND ANALYSIS**
14

15
16 149 **Study design and objectives**

17
18 150 The objectives of this study are to evaluate the performance of ULD CT for the detection of lung
19
20 151 nodules, and the evaluation of nodule characteristics in comparison to LD CT. Furthermore, as
21
22
23 152 smoking is a common risk factor, performance for the detection of cardiac and respiratory
24
25 153 associated diseases (bronchial abnormalities, emphysema, coronary calcifications) is also evaluated.
26
27 154 An additional ULD CT is performed in patients referred for non-enhanced chest CT for lung
28
29
30 155 nodules check-up or follow-up. The dose delivered with both acquisitions is still lower than the
31
32 156 French diagnostic reference level (6.65mSv). We chose to only include nodules ≥ 4 mm as the
33
34 157 incidence of cancer is very low below this threshold, and are not currently considered as clinically
35
36 158 significant (18). A 4 mm threshold was also used for the NLST study (2). In addition, fully calcified
37
38
39 159 nodules are excluded from the analysis because they are constantly benign and easily detected.

40
41 160 We will study nodule subtypes (solid, part-solid and pure ground-glass) and size. Furthermore we
42
43 161 will evaluate the performance of ULD CT to diagnose intrapulmonary lymph nodes, which are
44
45
46 162 benign nodules not needing follow up (19), and were not analyzed in previous ULD CT studies.

47
48 163 This trial sponsored by the Grenoble-Alpes University Hospital (CHUGA, France) is designed as a
49
50 164 monocentric, prospective, non-randomized study in which the patient is his own control. All
51
52
53 165 outcomes are evaluated by blinded double reading. Patient enrollment started in October 2017 and
54
55 166 is expected to be completed in September 2018. Figure 1 summarizes the process of inclusion,
56
57 167 intervention and reading, described in detail below.

58
59 168 **Primary outcome**
60

Detection rate (sensitivity) of lung nodules in ULD chest CT using the conventional chest LD CT as gold-standard.

Secondary outcomes

1) Diagnostic criteria: true positive (TP), false positive (FP), true negative (TN), false negative (FN), positive predictive value (PPV), negative predictive value (NPV), Specificity (Sp) of ULD CT

2) Concordance of nodule's size, subtype, and diagnosis of typical intrapulmonary lymph node among lung nodules between ULD and LD CT

3) Inter-observer reproducibility for size, subtype and diagnosis of lung nodules in ULD CT

4) Influence of subjects characteristics (age, sex, BMI), nodule location, and nodule size on lung nodule detection with ULD CT

5) Concordance of emphysema detection, type and distribution between ULD and LD CT

6) Concordance of Weston score of coronary calcifications between ULD and LD CT

7) Concordance of visual assessment of bronchial thickening, mucoid impaction or dilatation between ULD and LD CT

Eligibility Criteria

Inclusion criteria

- aged 18 years or older
- referred for non-enhanced chest CT for the following indications:
 - lung nodule check-up or follow-up
 - nodular abnormality on chest X ray
 - morphologic assessment of chronic obstructive pulmonary disease (COPD) or emphysema
 - asbestos exposure
 - assessment before lung radio frequency ablation

- assessment of disease extent of an extra thoracic cancer (in case of iodinated intravenous contrast agent contraindication)
- Check-up before extra-thoracic transplantation (in case of iodinated intravenous contrast agent contraindication).

Exclusion criteria

- Inability to lie down and stay still during the examination
- Inability to hold breath for more than 5 seconds
- Pneumonia in the last 3 months
- Body mass index (BMI) more than 35kg/m²
- Pregnant or breastfeeding women

CT scan acquisitions and reconstructions

The LD and ULD acquisitions are performed on the Revolution CT scanner (GE medical Healthcare, Milwaukee, WI, USA) equipped with the third generation ASIR-V iterative reconstruction. Acquisitions are performed successively in the same CT exam, in the supine position and at suspended full inspiration. Both acquisitions cover the same pulmonary fields from the apex to the costo-diaphragmatic angle, determined on the scout views (2 views).

The LD acquisition is the reference exam for the diagnosis of pulmonary nodules. The acquisition parameters are: spiral CT scanning; 120kVp; automatic modulation of 3D radiation dose ("Smart mA"+ Organ Dose Modulation) with lower bound 100mA, maximal bound 200mA and noise index 10; rotation time: 0.35sec ; modulation 35-70 mAs; pitch = 0.992 :1 and collimation: 80mm. The radiation dose, CTDIvol (volume CT dose index) and DLP (Dose Length Product = CTDIvol x length of exposure) may vary depending on patient attenuation and length of the acquisition. The expected DLP is between 70 and 200mGy.cm (0.98mSv to 2.8mSv) (the effective dose is calculated

by multiplying DLP by a thoracic conversion factor of 0.014 (20)), for an average DLP of 100mGy.cm.

The ULD CT acquisition parameters are: spiral CT scanning; 120kVp; fixed tube current of 10mA; rotation time: 0.35s; 3.5 mAs; pitch: 0.992 :1, collimation: 80mm. These parameters are fixed for all patients. The CTDIvol is constant at 0.24mGy. The DLP will depend only on the length of the acquired chest, different for each patient, expected around 10mGy.cm (0.14mSv). The modulation of the mA is deactivated to allow a very low tube current and therefore an ULD acquisition. The ULD acquisition increases the exam time by up to two minutes.

The reconstruction parameters are identical for both acquisitions: slice thickness: 1.25mm; standard filter and lung filter; contiguous 8-mm thickness Maximal Intensity projection (MIP) reconstruction, and iterative reconstruction with different percentages. We use ASIR-V in our study which is the latest generation of iterative reconstruction techniques. It blends hybrid iterative reconstruction and standard filtered back projection. The percentage of ASIR-V represents the amount of iterative reconstruction, from 0% (filtered back projection only) to 100% iterative reconstruction, which modifies image noise and texture. When designing our study, ASIR-V was not yet studied for chest CT. The CT vendor engineers suggested an empirical percentage between 40 up to 100%, depending on radiologist practice and preferences. We decided to test percentages of iterative reconstruction of 50% and 100%. The LD CT images are reconstructed with 50% ASIR-V (LD) and the ULD CT images with 50% (ULD50) and 100% (ULD100) ASIR-V.

The statistical analyses will be performed twice: with ULD50 and ULD100.

For every patient, CTDIvol and DLP are recorded. Effective dose and Size Specific Dose Estimates (SSDE) will be then calculated. Concerning the additional radiation for included patients, our ULD CT protocol has an expected effective dose between 0.10 and 0.20 mSv, which is about 6 to 20 times lower than the LD protocol (which is the usual dose in our institution for this indication), similar to a 2-views CXR, and to 30 days of natural radiation (21). Moreover, total dose of the entire exam (around 1.1 to 3 mSv) is lower than French diagnostic reference level of 6.65mSv.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Recruitment and intervention

Patients included in the study are those referred for a diagnostic chest CT without contrast media injection. On the day of the CT scan, a radiologist checks the eligibility criteria for the study, and informs the patient who signs a participation consent form if he accepts to join the study. The radiologist then collects the following parameters: height, weight, history of oncology, cardio-respiratory pathology and exposure to smoking. The patient then undergoes the standard diagnostic LD CT acquisition followed by the ULD acquisition. If, however, the dose of the LD acquisition is greater than 6.65mSv (French diagnostic reference level), the ULD acquisition is not performed and the patient is excluded from the data analysis. The patient's participation in the study is completed once he leaves the examination room.

The CT images of the LD acquisition are analysed by the radiologist who gives his medical report for the patient's medical management. If the number of nodules ≥ 4 mm identified on this acquisition is ≥ 6 in one lung, the patient will be excluded from the data analysis because the analysis of the outcomes will be too complicated to implement.

Patient and Public Involvement

Patients or public were not directly involved in the development of the research question. However, lowering the radiation dose is a rising concern for the patients and for public health. Patients were also not directly involved in the design, the recruitment and the conduct of this study.

As a regular medical care, the report of the diagnostic LD CT is sent to the prescribing physician, and to the patients at their request. According to French law, patients will be informed of the global results of the study at their request.

Blind reading of outcomes

For LD, ULD50 and ULD100 reconstructions, 2 radiologists will independently read all the radiological parameters. In order to limit the number of exams assessed by each reader, 4

radiologists split into 2 pairs will participate in the blind reading. Each pair of radiologists (1 junior and 1 senior radiologist) reads the three sets of images for the same patient in a random order. The term “blind” means that radiologists have neither knowledge of the patient's identity nor access to the results of diagnostic reading. To avoid patient identification, CT acquisitions are anonymized by deleting in the DICOM fields: the name, age and date of birth of the patient; the date and time of the examination and the name of the referring radiologist for the diagnosis. Each patient reconstruction is identified by a random number that differs for each of the two readers. Radiologists never read two series of the same patient consecutively. Anonymized exams are periodically transmitted to a pair with at least 15 LD, 15 ULD50 and 15 ULD100 reconstructions. The three patient reconstructions are not necessarily given the same day to both radiologists. In addition, the order of presentation is not identical for the two radiologists. The reading is performed on a diagnostic console (IMPAX software, 6.5.5.3502) (Agfa, Belgium) using Barco MDNC-3121 monitors (Barco, Courtrai, Belgium) and includes mediastinal and parenchymal filter reconstructions for each acquisition. The radiologist is free to adapt the level and width of the window to its reading practice (initial parenchymal window defined by a width of 1500UH and a level of -600UH), and to perform multiplanar reconstructions in the different plans of space. The reading also includes the additional MIP reconstruction for each acquisition, in order to sensitize the detection of nodules (22) (this type of reading from MIP series is performed in clinical routine). Radiologists identify nodules of longer diameter ≥ 4 mm by locating them with the slice number and the lobe. It is known that each lung has three lobes (right upper lobe, middle lobe, right lower lobe, culmen, lingula, and left lower lobe). Each radiologist completes a reading grid for each reconstruction with all detected nodule characteristics, evaluation of emphysema, coronary calcification and bronchial abnormalities. The completed grids are given to a Clinical Research Assistant for data entry and identification of discrepancies in identification of nodules between the two radiologists.

1

2 298 We consider that a nodule is the same between the two readers if:

3

4 299 • it is located in the same lobe

5

6 300 • the slice number is identical at ± 5 slices (a nodule will be visible on several successive
8 slices)

9

10 301
11 302 • the longest diameter of nodule is the same at ± 2 mm (23)

12

13
14 303 If these criteria are not respected or if a radiologist identifies one or more nodules in addition to or
15
16 304 less than the second radiologist, a consensus with a third CHUGA senior thoracic radiologist with
17
18 305 27 years of experience is obtained. This third radiologist is not part of the reading pairs. The
19
20 306 consensus is made from anonymized reconstructions and the reconstructions of the same patient are
21
22
23 307 not processed successively.

24

25 308 Besides, for every reconstruction is recorded:

26

- 27 309 - noise by measuring standard deviation in a region of interest placed in the tracheal air above
28
29 the carina,
30 310
31
32 311 - shape of the trachea which indicates inspiration degree,
33
34 312 - subjective image quality on a 3-point scale.
35

36

37 313

38

39 314 **Data monitoring**

40

41 315 All data is monitored by Grenoble-Alpes University Hospital (trial sponsor), in order to verify that
42
43 316 for every patient enrolled there is a signed consent form and that the inclusion and exclusion criteria
44
45
46 317 are respected. In addition all data collected in the case report form of every enrolled patient are
47
48 318 verified.

49

50 319

51

52 320 **Sample size**

53

54
55 321 With a 90% power, to have a sensitivity of detection of nodules with the ULD CT to 90% with a
56
57 322 confidence interval to $\pm 10\%$, it would be necessary to analyze 124 nodules. According to a
58
59 323 retrospective analysis of patients with indication of pulmonary nodule CT made at CHUGA, out of

60

420 patients per year with this indication, 210 present pulmonary nodules with a total of about 400 nodules. It should therefore include about 140 patients to have 124 nodules to be analyzed. Considering a 5% potential loss to follow-up or withdrawal of consent, the actual number of subjects to include is 147 in total. To this are added three potential patients who could be secondarily excluded from the study for a number of nodules ≥ 6 in one of the lungs. The total number of patients to include is 150. The sample size calculations were carried out using R software version 3.1.0 (library MKmisc, function power.diagnostic.test) (24, 25, 26).

Statistical analysis

In this non-randomized study where each patient is his own control, the threshold $p < 0.05$ will be taken into account to define the significance of the statistical tests. Analyses will be carried out in accordance with good statistical analysis practices after freezing of the database and will be carried out with the software R (version $\geq 3.1.0$). If the missing data rate of the primary criterion is between 5% and 20%, the missing data for this criterion will be replaced. The replacement of the missing data will be done, either according to a worst-case analysis strategy, by disfavoring the assumption that one seeks to demonstrate, either by a multiple imputation method. In case of multiple imputations, five imputations will be made, using a linear regression model taking into account the following variables: age, sex, BMI, smoking habit.

The normality of the quantitative parameters will be determined by the Shapiro-Wilks test or by graphical verification of the symmetry of the distribution. When the normality of the distribution of such a parameter has been demonstrated, it will be described by its mean and its standard deviation. Otherwise it will be described by its median, the 25th and the 75th percentile. The qualitative parameters will be expressed in number and percentage.

For the main objective, the sensitivity of the ULD CT (compared to the LD CT) for the detection of nodules will be calculated and accompanied by a 95% confidence interval. For secondary objective 1, the number of TP, FP, TN, FN, PPV, NPV and Sp of the ULD CT (compared to LD CT) will be

1
2 350 calculated. For secondary objectives 2, 5, 6 and 7, the concordance of the qualitative variables will
3
4 351 be evaluated using the kappa coefficient. The concordance of the quantitative variables will be
5
6 352 evaluated using Lin's concordance coefficient. For each coefficient, the 95% confidence interval
7
8
9 353 will be given. For secondary objective 3, inter-observer reproducibility for qualitative variables will
10
11 354 be evaluated using the kappa coefficient. It will be evaluated, for the quantitative variables, using
12
13 355 the ICC (intra class coefficient). For each coefficient, the 95% confidence interval will be given.
14
15
16 356 For secondary objective 4, a logistic regression model will be implemented. The variable to be
17
18 357 explained will be the result of detecting each nodule in ULD CT compared to the LD CT (0 = good
19
20 358 detection / 1 = bad detection). The explanatory variables will be the age, sex and BMI of the patient,
21
22
23 359 the location (lobe) and the size of the nodule. The size of the nodule can be used as a qualitative
24
25 360 variable (<5mm, 5-10mm,> 10mm).
26
27 361 An interim analysis including the analysis of the primary endpoint will be performed after inclusion
28
29 362 of the first 50 patients. This interim analysis will aim to: decide whether to continue or stop the
30
31 363 study for futility and readjust the number of patients if necessary (if the characteristics of the
32
33 364 patients included do not correspond to those initially planned (too many patients without nodules ≥ 4
34
35 365 mm)). In order to maintain an overall threshold of 5% in the final analysis, the interim analysis will
36
37 366 be carried out with a threshold of 0.1%. The results of the interim analysis will be taken into
38
39 367 account by the steering committee to propose modifications to the analysis plan. For this interim
40
41 368 analysis, data from the confrontation between the two radiologists will be used.
42
43
44
45
46 369

47
48 370 **Limitations**

49
50 371 First limitation of our protocol is that we do not have a true screening population because there is no
51
52 372 organized lung cancer screening program in our country yet. Therefore, our study population
53
54
55 373 corresponds to patients routinely referred for lung nodule checkup or follow up instead of a risk-
56
57 374 factor based population.
58
59
60

Another limitation is that ULD CT is easily recognizable as the image noise is increased as compared to LD CT, as well as ULD 50 and ULD 100 are possible to distinguish for an experienced radiologist. As a consequence, readers were not blinded for these, but for patient name, sex, age, clinical status, and CT report.

Recall bias is limited by a randomized order of presentation and cutting into several reading sessions.

Although we wanted to have a “western population”, we decided not to include obese patients with a BMI>35, because ULD CT are of poorer quality, due to the need of more radiation-exposure to produce acceptable images. Vardhanabhuti and al. recently found a loss of nodule detection with iterative reconstructed CT scanners at an effective dose of $0.14\pm0.01\text{mSv}$ for obese patients with BMI>38 (27).

We decided to test percentage of 50 and 100% of ASIR-V. Tang and al. tested ASIR-V from 10 to 100% in non-enhanced chest and showed ASIR-V has greater potential in reducing image noise and artifacts and maintaining image sharpness when compared to ASIR, and 60% ASIR-V had the highest image quality combining both the objective and subjective evaluation of images (28). This finding, although occurring after the design of our study is close to our chosen 50% level of ASIR-V.

FUNDING

This trial is funded by the Delegation to Clinical Research and Innovation (DRCI) of Grenoble-Alpes University Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

AUTHOR CONTRIBUTIONS

M. Ludwig is the corresponding author and contributed to the conception of the study, to the inclusion of patients, to the blind reading of outcomes and to the drafting of the manuscript.

1
2 401 E. Chipon contributed to the conception of the study, to the drafting of the manuscript, and is
3
4 402 responsible for data management and its integrity.
5
6 403 J. Cohen contributed to the conception of the study, to the inclusion of patients, to the blind reading
7
8 404 of outcomes and to the revision of the manuscript.
9
10
11 405 E. Reymond contributed to the inclusion of patients, to the blind reading of outcomes and to the
12
13 406 revision of the manuscript.
14
15
16 407 M. Medici contributed to the design and application of statistical analysis, and to the drafting of the
17
18 408 manuscript.
19
20 409 A. Cole contributed to the blind reading of outcomes and to the revision of the manuscript.
21
22
23 410 A. Moreau Gaudry contributed to the conception of the study and to the revision of the manuscript.
24
25 411 G R Ferretti is the principal investigator of the study and contributed to the conception of the work,
26
27 412 to the inclusion of patients, to the blind consensus of outcomes and to the revision of the
28
29 413 manuscript.
30
31
32 414 All authors approved the final manuscript and agreed to be accountable for all aspects of the work.
33
34 415

36 416 **COMPETING INTERESTS**

38
39 417 The authors declare that they have no competing interests
40
41 418

43 419 **CONSENT FOR PUBLICATION**

45
46 420 Not applicable
47
48 421

50 422 **ETHICS AND DISSEMINATION**

52
53 423 This trial is registered on the ClinicalTrials.gov database (reference NCT03305978) (see
54
55 424 supplementary file “trial registration data set”), and was approved by the relevant ethical committee
56
57 425 (Comité de Protection des Personnes, CPP sud-est VI, France, 07/07/2017, CPP Reference:
58
59 426 AU1342). The Protocol version is N°1.0- Date: May 4th 2017
60

All patients sign a consent form before being enrolled in the trial, in accordance with the Declaration of Helsinki II.

Once the statistical report is finalized, we plan to publish our results in an international scientific journal and present them in national and international congresses.

DATA STATEMENT

Legal restrictions (French personal data laws) prohibit the authors from making the minimal data set publicly available. These data are available upon request.

ACKNOWLEDGEMENTS

The authors thank Alexandre Rey and Pierre Pittet for their help to collect and prepare data, Tarek Ittobane for data monitoring, Dr A. Jankowski for the inclusion of patients, and Laura Cotarla for English proofreading.

REFERENCES

1. Globocan : Lung Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx)
2. National Lung Screening Trial Research Team, Denise R. Aberle, Amanda M. Adams, Christine D. Berg, William C. Black, Jonathan D. Clapp, Richard M. Fagerstrom, et al. "Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening." *The New England Journal of Medicine* 365, no. 5 (August 4, 2011): 395–409. doi:10.1056/NEJMoa1102873
3. Yousaf-Khan U, van der Aalst C, de Jong PA, et al."Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval." *Thorax* 2017;72:48-56. 10.1136/thoraxjnl-2016-208655

4. Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation and National Research Council. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, D.C: The National Academies Press; 2006
5. Kubo T, Ohno Y, Seo JB, Yamashiro T, Kalender WA, Lee CH, et al. "Securing safe and informative thoracic CT examinations-Progress of radiation dose reduction techniques". *Eur J Radiol*. 2017 Jan;86:313–9.
6. Kim, Yookyung, Yoon Kyung Kim, Bo Eun Lee, SeokJeong Lee, YonJuRyu, Jin Hwa Lee, and Jung Hyun Chang. "Ultra-Low-Dose CT of the Thorax Using Iterative Reconstruction: Evaluation of Image Quality and Radiation Dose Reduction." *AJR. American Journal of Roentgenology* 204, no. 6 (June 2015): 1197–1202. doi:10.2214/AJR.14.13629.
7. Vardhanabhuti, Varut, Robert J. Loader, Grant R. Mitchell, Richard D. Riordan, and Carl A. Roobottom. "Image Quality Assessment of Standard- and Low-Dose Chest CT Using Filtered Back Projection, Adaptive Statistical Iterative Reconstruction, and Novel Model-Based Iterative Reconstruction Algorithms." *AJR. American Journal of Roentgenology* 200, no. 3 (March 2013): 545–52. doi:10.2214/AJR.12.9424.
8. Ichikawa, Yasutaka, Kakuya Kitagawa, Naoki Nagasawa, Shuichi Murashima, and Hajime Sakuma. "CT of the Chest with Model-Based, Fully Iterative Reconstruction: Comparison with Adaptive Statistical Iterative Reconstruction." *BMC Medical Imaging* 13 (2013): 27. doi:10.1186/1471-2342-13-27.
9. Padole, Atul, Sarabjeet Singh, Jeanne B. Ackman, Carol Wu, Synho Do, Sarvenaz Pourjabbar, Ranish Deedar Ali Khawaja, et al. "Submillisievert Chest CT with Filtered Back Projection and Iterative Reconstruction Techniques." *AJR. American Journal of Roentgenology* 203, no. 4 (October 2014): 772–81. doi:10.2214/AJR.13.12312.
10. Montet, Xavier, Anne-Lise Hachulla, Angeliki Neroladaki, Frederic Lador, Thierry Rochat, Diomidis Botsikas, and Christoph D. Becker. "Image Quality of Low mA CT Pulmonary Angiography Reconstructed with Model Based Iterative Reconstruction versus Standard CT


- Pulmonary Angiography Reconstructed with Filtered Back Projection: An Equivalency Trial." *EuropeanRadiology* 25, no. 6 (June 2015): 1665–71. doi:10.1007/s00330-014-3563-5.
11. Yoon, Hyun Jung, Myung Jin Chung, Hye Sun Hwang, Jung Won Moon, and Kyung Soo Lee. "Adaptive Statistical Iterative Reconstruction-Applied Ultra-Low-Dose CT with Radiography-Comparable Radiation Dose: Usefulness for Lung Nodule Detection." *Korean Journal of Radiology* 16, no. 5 (October 2015): 1132–41. doi:10.3348/kjr.2015.16.5.1132
12. Sui, Xin, Felix G. Meinel, Wei Song, Xiaoli Xu, Zixing Wang, Yuyan Wang, Zhengyu Jin, Jiahong Chen, Rozemarijn Vliegenthart, and U. Joseph Schoepf. "Detection and Size Measurements of Pulmonary Nodules in Ultra-Low-Dose CT with Iterative Reconstruction Compared to Low Dose CT." *European Journal of Radiology* 85, no. 3 (March 2016): 564–70. doi:10.1016/j.ejrad.2015.12.013
13. Nagatani Y, Takahashi M, Murata K, Ikeda M, Yamashiro T, Miyara T, Koyama H, Koyama M, Sato Y, Moriya H, et al "Lung nodule detection performance in five observers on computed tomography (CT) with adaptive iterative dose reduction using three-dimensional processing (AIDR 3D) in a Japanese multicenter study: Comparison between ultra-low-dose CT and low-dose CT by receiver-operating characteristic analysis". *Eur J Radiol.* 2015 Jul; 84(7):1401-12. Epub 2015 Apr 2
14. Huber, Adrian, Julia Landau, Lukas Ebner, Yanik Bütikofer, Lars Leidolt, Barbara Brela, Michelle May, Johannes Heverhagen, and Andreas Christe. "Performance of Ultralow-Dose CT with Iterative Reconstruction in Lung Cancer Screening: Limiting Radiation Exposure to the Equivalent of Conventional Chest X-Ray Imaging." *EuropeanRadiology*, January 26, 2016. doi:10.1007/s00330-015-4192-3
15. Messerli M, Kluckert T, Knitel M, Wälti S, Desbiolles L, Rengier F, et al. "Ultralow dose CT for pulmonary nodule detection with chest x-ray equivalent dose - a prospective intra-individual comparative study". *EurRadiol.* 2017 Aug;27(8):3290–9.

16. Neroladaki, Angeliki, Diomidis Botsikas, Sana Boudabbous, Christoph D. Becker, and Xavier Montet. "Computed Tomography of the Chest with Model-Based Iterative Reconstruction Using a Radiation Exposure Similar to Chest X-Ray Examination: Preliminary Observations." *EuropeanRadiology* 23, no. 2 (February 2013): 360–66. doi:10.1007/s00330-012-2627-7.
17. De Marco P, Origgi D. "New adaptive statistical iterative reconstruction ASiR-V: Assessment of noise performance in comparison to ASiR". *J Appl Clin Med Phys*. 2018 Mar;19(2):275-286. doi: 10.1002/acm2.12253. Epub 2018 Jan 24. PubMed PMID: 29363260; PubMed Central PMCID: PMC5849834
18. Gierada DS, Pinsky P, Nath H, Chiles C, Duan F, Aberle DR. "Projected outcomes using different nodule sizes to define a positive CT lung cancer screening examination". *J Natl Cancer Inst*. 2014;106:dju284.
19. Ahn MI, Gleeson TG, Chan IH et-al. "Perifissural nodules seen at CT screening for lung cancer". *Radiology*. 2010;254 (3): 949-56. doi:10.1148/radiol.09090031
20. Task Group on Control of Radiation Dose in Computed Tomography. "Managing Patient Dose in Computed Tomography. A Report of the International Commission on Radiological Protection." *Annals of the ICRP* 30, no. 4 (2000): 7–45
21. Exposition de la population française aux rayonnements ionisants liée aux actes de diagnostic médical en 2012. Rapport IRSN PRP-HOM N°2014-6
22. Jankowski, A., T. Martinelli, J. F. Timsit, C. Brambilla, F. Thony, M. Coulomb, and G. Ferretti. "Pulmonary Nodule Detection on MDCT Images: Evaluation of Diagnostic Performance Using Thin Axial Images, Maximum Intensity Projections, and Computer-Assisted Detection." *European Radiology* 17, no. 12 (December 2007): 3148–56. doi:10.1007/s00330-007-0727-6.

23. Revel MP, Bissery A, Bienvenu M, Aycard L, Lefort C, Fria G. Are two-dimensional CT measurements of small noncalcified pulmonary nodules reliable? *Radiology*. 2004 May;231(2):453-8. PubMed PMID: 15128990.
24. A. Flahault, M. Cadilhac, and G. Thomas (2005). Sample size calculation should be performed for design accuracy in diagnostic test studies. *Journal of Clinical Epidemiology*, 58(8):859-862.
25. H. Chu and S.R. Cole (2007). Sample size calculation using exact methods in diagnostic test studies. *Journal of Clinical Epidemiology*, 60(11):1201-1202.
26. M.R. Chernick and C.Y. Liu (2002). The saw-toothed behavior of power versus sample size and software solutions: single binomial proportion using exact methods. *Am Stat*, 56:149-155.
27. Vardhanabhuti V, Pang CL, Tenant S, Taylor J, Hyde C, Roobottom C. "Prospective intra-individual comparison of standard dose versus reduced-dose thoracic CT using hybrid and pure iterative reconstruction in a follow-up cohort of pulmonary nodules-Effect of detectability of pulmonary nodules with lowering dose based on nodule size, type and body mass index". *Eur J Radiol*. 2017 Jun;91:130-141. doi: 10.1016/j.ejrad.2017.04.006
28. Tang H, Yu N, Jia Y, Yu Y, Duan H, Han D, et al. "Assessment of noise reduction potential and image quality improvement of a new generation adaptive statistical iterative reconstruction (ASIR-V) in chest CT". *Br J Radiol*. 2018 Jan;91(1081):20170521

FIGURE 1 legend:

Study Flow chart. ASIR-V[®], adaptive statistical iterative reconstruction-Véo (GE medical Healthcare, Milwaukee, WI, USA); CT, computed tomography; LD, low dose; LD50, low dose CT with 50% ASIR-V reconstruction; ULD, ultra-low dose; ULD50, ultra-low dose CT with 50% ASIR-V reconstruction, ULD 100, ultra-low dose CT with 100% ASIR-V reconstruction



Study Flow chart. ASIR-V ®, adaptive statistical iterative reconstruction-Véo (GE medical Healthcare, Milwaukee, WI, USA); CT, computed tomography; LD, low dose; LD50, low dose CT with 50% ASIR-V reconstruction; ULD, ultra-low dose; ULD50, ultra-low dose CT with 50% ASIR-V reconstruction, ULD 100, ultra-low dose CT with 100% ASIR-V reconstruction.

210x297mm (300 x 300 DPI)

Trial registration data set :

Primary registry and trial identifying number	ClinicalTrials.gov NCT03305978
Date of registration in primary registry	September 26, 2017
Secondary identifying numbers	38RC17.132
Source(s) of monetary or material support	University Hospital, Grenoble
Primary sponsor	University Hospital, Grenoble
Secondary sponsor(s)	French Thoracic Imaging Society
Contact for public queries	Emilie CHIPON, PhD, +33476767313, echipon@chu-grenoble.fr
Contact for scientific queries	Gilbert FERRETTI, MD PhD, +3376767313, gferretti@chu-grenoble.fr
Public title	Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan.
Scientific title	Detection of Pulmonary Nodules: Comparison of Ultra-low-dose Chest CT (Approaching a Two Views Chest X-ray Radiation) and Standard Low Dose CT. A Monocentric, Prospective, Non-randomized, Comparative, Open-label Study With Blind Reading of the Judgment Criteria
Country of recruitment	France
Health condition(s) or problem(s) studied	Lung cancer screening, radiation exposure
Intervention(s)	<p><u>Device: Ultra low dose chest CT</u> An additional ultra low dose CT row is performed for every subject besides standard diagnostic low dose chest CT. Other Name: Revolution CT (GE Healthcare) 442507CN0, equipped with ASIR V</p> <p><u>Device: Low dose chest CT</u> standard diagnostic low dose chest CT Other Name: Revolution CT (GE Healthcare)</p>
Key inclusion and exclusion criteria	<p>Ages eligible for study: ≥ 18 years Sexes eligible for study: both Accepts healthy volunteers: no</p> <p><u>Inclusion criteria :</u> Patients referred for non enhanced chest CT for following indications :</p> <ul style="list-style-type: none"> - lung nodule search or control - nodular abnormality on chest X ray - statement of COPD or emphysema - asbestos exposure - nodule localization before radio frequency ablation - assessment of disease extent of an extra thoracic cancer (in case of iodinated intravenous contrast agent contraindication) - statement before extrathoracic transplantation (in case of iodinated intravenous contrast agent contraindication) <p>Affiliated with the french social security Who signed consent</p> <p><u>Exclusion criteria :</u> Inability to lie down and stay still during the examination Inability to hold breath more than 5 seconds Pneumonia in the last 3 months Body mass index more than 35kg/m² exclusion period of another interventionnal study</p>

	referred for articles L1121-5 to L1121-8 of french public health code Pregnant or breastfeeding women
Study type	<p>Interventional</p> <p><u>Allocation</u>: Non-Randomized</p> <p><u>Intervention Model</u>: Sequential Assignment</p> <p><u>Intervention Model Description</u>: Major Patient Addressed for Thoracic CT without Injection of Contrast</p> <p><u>Masking</u>: Single (Outcomes Assessor)</p> <p><u>Masking Description</u>: blinding evaluation of criteria</p> <p><u>Primary purpose</u>: diagnostic</p>
Date of first enrolment	October 3, 2017
Target sample size	150
Recruitment status	Recruiting
Primary outcome(s)	<p>Ultra low dose CT lung nodule detection sensibility [Time Frame: 22 months]</p> <p>Detection rate (%) of ≥ 4mm lung nodules in ultra low dose chest CT versus standard low</p>
Key secondary outcomes	<ul style="list-style-type: none"> - Ultra low dose CT diagnostic performances of lung nodule detection [Time Frame: 22 months] :true positives, false positives, true negatives, false negatives, positive predictive value, negative predictive value, specificity, of ≥ 4mm lung nodules detection within ultra low dose chest CT versus standard low dose chest CT - Concordance of ≥ 4mm lung nodules characteristics between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : comparison of size, density, type (true nodule or intrapulmonary ganglion) of ≥ 4mm lung nodule between ultra low dose and standard low dose chest CT - Ultra low dose CT inter-observer reproducibility [Time Frame: 22 months] : inter observer reproducibility for size, density and type of ≥ 4mm lung nodule detected in ultra low dose CT - Influence of subjects characteristics, nodule location, and nodule size on detection between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : analysis of subjects characteristics (age, gender, body mass index), ≥ 4mm nodule location, and ≥ 4 mm nodule size on detection between ultra low dose and standard low dose chest CT - Concordance of emphysema characteristics between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : comparison of emphysema detection, type (centrilobular, paraseptal, panlobular, bullous) and distribution between ultra low dose and standard low dose chest CT - Concordance of coronary calcification detection and quantification between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : Comparison of Weston scores between ultra low dose and standard low dose chest CT - Concordance of bronchial abnormalities evaluation between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : comparison of detection of bronchial thickening or dilatation between ultra low dose and standard low dose chest CT
Ethics Review	approved by the relevant ethical committee (Comité de Protection des Personnes, CPP Sud-Est VI, France, CPP Reference: AU1342), on July 7, 2017

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	17
Protocol version	#3	Date and version identifier	18
Funding	#4	Sources and types of financial, material, and other support	16
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1;16
Roles and responsibilities:	#5b	Name and contact information for the trial sponsor	2

1	sponsor contact			
2	information			
3				
4	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	16
5	responsibilities:		collection, management, analysis, and interpretation of	
6	sponsor and funder		data; writing of the report; and the decision to submit the	
7			report for publication, including whether they will have	
8			ultimate authority over any of these activities	
9				
10				
11				
12	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	n/a
13	responsibilities:		centre, steering committee, endpoint adjudication	
14	committees		committee, data management team, and other individuals or	
15			groups overseeing the trial, if applicable (see Item 21a for	
16			data monitoring committee)	
17				
18				
19				
20	Background and	#6a	Description of research question and justification for	5
21	rationale		undertaking the trial, including summary of relevant studies	
22			(published and unpublished) examining benefits and harms	
23			for each intervention	
24				
25				
26				
27	Background and	#6b	Explanation for choice of comparators	6
28	rationale: choice of			
29	comparators			
30				
31				
32	Objectives	#7	Specific objectives or hypotheses	7
33				
34				
35	Trial design	#8	Description of trial design including type of trial (eg, parallel	7
36			group, crossover, factorial, single group), allocation ratio,	
37			and framework (eg, superiority, equivalence, non-inferiority,	
38			exploratory)	
39				
40				
41				
42	Study setting	#9	Description of study settings (eg, community clinic,	7
43			academic hospital) and list of countries where data will be	
44			collected. Reference to where list of study sites can be	
45			obtained	
46				
47				
48	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	8
49			eligibility criteria for study centres and individuals who will	
50			perform the interventions (eg, surgeons, psychotherapists)	
51				
52				
53				
54	Interventions:	#11a	Interventions for each group with sufficient detail to allow	10
55	description		replication, including how and when they will be	
56			administered	
57				
58				
59				
60				

Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	11
Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	n/a
Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	n/a
Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	8
Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	7
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	13
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	11
Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	n/a
Allocation concealment	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed	n/a

1	mechanism		envelopes), describing any steps to conceal the sequence	
2			until interventions are assigned	
3				
4	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	n/a
5	implementation		participants, and who will assign participants to	
6			interventions	
7				
8				
9	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	11
10			trial participants, care providers, outcome assessors, data	
11			analysts), and how	
12				
13				
14	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	n/a
15	emergency		permissible, and procedure for revealing a participant's	
16	unblinding		allocated intervention during the trial	
17				
18				
19				
20	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	12
21			and other trial data, including any related processes to	
22			promote data quality (eg, duplicate measurements, training	
23			of assessors) and a description of study instruments (eg,	
24			questionnaires, laboratory tests) along with their reliability	
25			and validity, if known. Reference to where data collection	
26			forms can be found, if not in the protocol	
27				
28				
29				
30				
31	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	n/a
32	retention		up, including list of any outcome data to be collected for	
33			participants who discontinue or deviate from intervention	
34			protocols	
35				
36				
37				
38	Data management	#19	Plans for data entry, coding, security, and storage, including	13
39			any related processes to promote data quality (eg, double	
40			data entry; range checks for data values). Reference to	
41			where details of data management procedures can be	
42			found, if not in the protocol	
43				
44				
45				
46	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	13
47			outcomes. Reference to where other details of the statistical	
48			analysis plan can be found, if not in the protocol	
49				
50				
51				
52	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	14
53	analyses		adjusted analyses)	
54				
55				
56	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	13
57	population and		adherence (eg, as randomised analysis), and any statistical	
58	missing data		methods to handle missing data (eg, multiple imputation)	
59				
60				

1 Data monitoring: 2 formal committee	#21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	13
11 Data monitoring: 12 interim analysis	#21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	14
16 Harms	#22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	n/a
21 Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a
27 Research ethics 28 approval	#24	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	16
31 Protocol 32 amendments	#25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	n/a
37 Consent or assent	#26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	16
43 Consent or assent: 44 ancillary studies	#26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
48 Confidentiality	#27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	n/a
55 Declaration of 56 interests	#28	Financial and other competing interests for principal investigators for the overall trial and each study site	16
58 Data access	#29	Statement of who will have access to the final trial dataset,	19

			and disclosure of contractual agreements that limit such access for investigators	
	Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
	Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	16
	Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
	Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
	Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	n/a
	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a

The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 23. July 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Detection of pulmonary nodules: a clinical study protocol to compare ultra-low dose chest CT and standard low-dose CT using ASIR-V.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025661.R2
Article Type:	Protocol
Date Submitted by the Author:	16-Apr-2019
Complete List of Authors:	Ludwig, Marie; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine Chipon, Emilie; INSERM, CIC 1406; Centre Hospitalier Universitaire Grenoble Alpes, pôle recherche Cohen, Julien; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine Reymond, Emilie; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie Medici, Maud; INSERM, CIC 1406; Centre Hospitalier Universitaire Grenoble Alpes, pôle recherche Cole, Anthony; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine Moreau Gaudry, Alexandre; INSERM, CIC 1406; Centre Hospitalier Universitaire Grenoble Alpes, pôle recherche Ferretti, Gilbert; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine
Primary Subject Heading:	Radiology and imaging
Secondary Subject Heading:	Oncology, Respiratory medicine, Smoking and tobacco
Keywords:	low dose computed tomography, ultra low dose computed tomography, pulmonary nodule, lung cancer screening, iterative reconstruction

SCHOLARONE™
Manuscripts

Service de radiologie diagnostique et thérapeutique, CHU Grenoble Alpes, CS 10217, 38043
Grenoble CEDEX 9, France

28

Sponsor:

Delegation to Clinical Research and Innovation (DRCI) of Grenoble-Alpes University Hospital
CHU Grenoble-Alpes, Pôle Recherche, F-38000 Grenoble, France
+33476767575

33

34

35

KEYWORDS

Low dose computed tomography, Ultra low-dose computed tomography, pulmonary nodule, Lung
cancer screening, iterative reconstruction

39

40

Word count, excluding title page, abstract, article summary, references, figures, tables, and
acknowledgements : 4047

43

44

45

46

47

1
2 48 **ABSTRACT**

3
4 49 Introduction:

5
6 50 Lung cancer screening in individuals at risk has been recommended by various scientific institutions.
7
8 51 One of the main concerns for CT screening is repeated radiation exposure, with the risk of inducing
9
10 52 malignancies in healthy individuals. Therefore, lowering the radiation dose is one of the main
11
12 53 objectives for radiologists. The aim of this study is to demonstrate that an ultra-low dose (ULD) chest
13
14 54 CT protocol, using recently introduced hybrid iterative reconstruction (ASiR-V, GE medical
15
16 55 Healthcare, Milwaukee, WI, USA), is as performant as a standard “low dose” (LD) CT to detect non
17
18 56 calcified lung nodules $\geq 4\text{mm}$.

19
20
21
22 57 Methods and analysis:

23
24 58 The total number of patients to include is 150. Those are referred for non-enhanced chest CT for
25
26 59 detection or follow-up of lung nodule and will undergo an additional unenhanced ULD CT
27
28 60 acquisition, the dose of which is on average 10 times lower than the conventional LD acquisition.
29
30 61 Total dose of the entire exam (LD + ULD) is lower than the French diagnostic reference level for a
31
32 62 chest CT (6.65 milliSievert). ULD CT images will be reconstructed with 50% and 100% ASIR-V,
33
34 63 and LD CT with 50%. The 3 sets of images will be read in random order by two pair of radiologists,
35
36 64 in a blind test, where patient identification and study outcomes are concealed. Detection rate
37
38 65 (sensitivity) is the primary outcome. Secondary outcomes will include concordance of nodule
39
40 66 characteristics; inter-observer reproducibility; influence of subjects’ characteristics, nodule location,
41
42 67 and nodule size; and concordance of emphysema, coronary calcifications evaluated by visual scoring
43
44 68 and bronchial alterations between LD and ULD CT. In case of discordance, a third radiologist will
45
46 69 arbitrate.

47
48
49
50 70 Ethics and dissemination:

51
52 71 The study was approved by the relevant ethical committee. Each study participant will sign an
53
54 72 informed consent form.

55
56 73 **Trial registration number:** *Clinicaltrials.gov* NCT03305978

ARTICLE SUMMARY:

STRENGTHS AND LIMITATIONS OF THIS STUDY

- We will evaluate the sensitivity of an ultra-low dose CT, delivering 10 times less radiation than conventional low-dose CT, to detect lung nodules, in a French population of 150 patients referred for lung nodule check-up or follow-up.
- We will use a recently introduced hybrid iterative reconstruction (ASiR-V) and different levels of ASiR-V will be assessed
- Nodules characteristics will be analyzed in particular the diagnosis of intrapulmonary lymph node, which is a benign lesion.
- Patients with morbid obesity (BMI>35) will not be included as image quality of ultra-low dose CT is not acceptable for those morphotypes.
- Readers will be aware of the type of CT acquisition (LD and ULD) and reconstruction, because they are easily recognizable due to the different level of image noise.

1
2 91 **INTRODUCTION**

3
4 92 Lung cancer is the deadliest cancer in the world (1), mainly due to the fact that it is often diagnosed
5
6
7 93 at advanced stages that are not surgically curable. The current challenge is therefore to detect lung
8
9 94 cancer at early asymptomatic stages. Risk factors such as smoking and occupational exposure (mainly
10
11 95 asbestos, silica, arsenic, chromium, iron, coal, ionising radiation) are well known and enable to define
12
13 96 the target population for such programs.

14
15
16 97 The National Lung Screening Trial (NLST) was the first study to show that a low dose (LD) (average
17
18 98 effective dose of 1.5mSv) computed tomography (CT) lung cancer screening reduced specific death
19
20 99 by 20% (95% CI, 6.8 to 26.7; P=0.004) as compared with chest X Ray (CXR) screening (single-view
21
22
23 100 posteroanterior) in actual or former smokers (>30 pack years) patients between 55 and 74 years old
24
25 101 (2).

26
27 102 Other lung cancer screening studies are still in progress in Europe, such as the NELSON study in
28
29
30 103 Belgium and the Netherlands, the results of which are expected to be reported soon (3)

31
32 104 However, the drawback of using LD CT at such doses (<1.5 millisievert (mSv)) is that even though
33
34 105 irradiating less than standard chest CT, the radiation exposure is still on average 10 times higher than
35
36 106 a 2 views CXR, and may be a risk for induced malignancies in itself. (4)

37
38
39 107 In this context, great efforts are currently being made by CT manufacturers to reduce the dose and
40
41 108 maintain diagnostic quality. Technologies such as automated exposure control, lower tube current
42
43 109 and iterative reconstruction (5), were recently introduced, enabling further dose decrease for chest
44
45
46 110 CTs, and the concept of “ultra-low dose (ULD) CT” (or submillisievert CT), which delivers a
47
48 111 radiation dose approaching that of 2 CXR views at the cost of a slight deterioration of the image
49
50 112 quality (6). Among these technological advances, the most significant is probably the new iterative
51
52
53 113 reconstruction whether full iterative or hybrid. (7,8,9,10)

54
55 114 Promising results have been published for lung nodule detection with ULD CT (11,12,13). However,
56
57 115 these studies were conducted on Asian populations, which may have different morphotypes compared
58
59 116 to Caucasian populations.

Huber and al. performed a phantom study comparing standard, LD and ULD CT for detection of pulmonary nodules. When compared to standard CT, the detection rate was 95.5% for LD CT (1.76 mSv), and 93.3% for ULD CT (0.13mSv), increasing at 97.5% when adding computer aided diagnosis and maximal intensity projection (14).

Since we started to design our study protocol, Messerli and al. published a study including 202 patients referred for any clinically indicated chest CT. 91.2% nodules were detected using ULD CT (0.13 \pm 0.01mSv) as compared to LD CT (1.8 \pm 0.7 mSv). Sensitivity was significantly higher for larger nodule diameter, lower BMI patients, lower image noise and for solid and calcified nodules (15).

Neroladaki and al. showed the same number of detected nodules between an ULD acquisition (0.16 \pm 0.006mSv) with iterative reconstruction and a standard dose filtered back projection acquisition (11.2 \pm 2.7mSv), and more nodules detected with model based iterative reconstruction (MBIR) than adaptive statistical iterative reconstruction (ASIR) (16). MBIR is known to better minimize image noise compared to ASIR : Ichikawa and al found a significantly lower image noise with LD (1.6 \pm 0.8 mSv) MBIR CT (11.6 \pm 1.0 Hounsfield units (HU)) than with LD ASIR CT (21.1 \pm 2.6 HU, $p < 0.0005$), a slightly better image quality score for decreased lung attenuation lesion, and no difference in image quality scores for consolidation or mass, ground-glass attenuation, or reticular opacity with MBIR compared to ASIR LD CT (8). But MBIR may slightly deteriorate lesion margin (9), and significantly increases reconstruction time, taking more than 30 minutes, when patients lie less than 10 minutes in the machine. ASIR-V is the latest generation of hybrid iterative reconstruction (GE medical Healthcare, Milwaukee, WI). It combines ASIR and MBIR and enables a better noise reduction than ASIR, with a processing time of only few minutes, suitable to a routine chest CT session (17).

According to the ALARA (as low as reasonably achievable) principle, we hope to validate our ULD chest CT protocol (<0.2mSv), the dose of which is 10 times lower than a usual LD CT, as a sensitive

1
2 143 tool to detect lung nodules. Thus, this ULD CT acquisition could be generalized for lung nodules
3
4 144 detection and would consolidate the setup of lung cancer screening programs. Also, this would allow
5
6 145 the generalization of ULD protocols, for radiation sensitive populations (children and young adults
7
8
9 146 in particular).

10
11 147
12

13
14 148 **METHODS AND ANALYSIS**

15
16 149 **Study design and objectives**

17
18 150 The objectives of this study are to evaluate the performance of ULD CT for the detection of lung
19
20 151 nodules, and the evaluation of nodule characteristics in comparison to LD CT. Furthermore, as
21
22
23 152 smoking is a common risk factor, performance for the detection of cardiac and respiratory associated
24
25 153 diseases (bronchial abnormalities, emphysema, coronary calcifications) is also evaluated.

26
27 154 An additional ULD CT is performed in patients referred for non-enhanced chest CT for lung nodules
28
29
30 155 check-up or follow-up. The dose delivered with both acquisitions is still lower than the French
31
32 156 diagnostic reference level (6.65mSv). We chose to only include nodules ≥ 4 mm as the incidence of
33
34 157 cancer is very low below this threshold, and are not currently considered as clinically significant (18).
35
36 158 Nodules < 3 mm are considered as micronodules and the recommendation from the Fleischner Society
37
38
39 159 recommends that such nodules should not be measured, given inherent accuracy limitations and
40
41 160 variability in determining whether the lesion is a solid, part-solid, or ground-glass nodule (19). A 4
42
43 161 mm threshold was also used for the NLST study (2). In addition, fully calcified nodules are excluded
44
45
46 162 from the analysis because they are constantly benign and easily detected.

47
48 163 We will study nodule subtypes (solid, part-solid and pure ground-glass) and size. Furthermore we
49
50 164 will evaluate the performance of ULD CT to diagnose intrapulmonary lymph nodes, which are benign
51
52
53 165 nodules not needing follow up (20), and were not analyzed in previous ULD CT studies.

54
55 166 This trial sponsored by the Grenoble-Alpes University Hospital (CHUGA, France) is designed as a
56
57 167 monocentric, prospective, non-randomized study in which the patient is his own control. All
58
59
60 168 outcomes are evaluated by blinded double reading. Patient enrollment started in October 2017 and is

expected to be completed in September 2018. [Figure 1](#) summarizes the process of inclusion, intervention and reading, described in detail below.

Primary outcome

Detection rate (sensitivity) of lung nodules in ULD chest CT using the conventional chest LD CT as gold-standard.

Secondary outcomes

- 1) Diagnostic criteria: true positive (TP), false positive (FP), true negative (TN), false negative (FN), positive predictive value (PPV), negative predictive value (NPV), Specificity (Sp) of ULD CT
- 2) Concordance of nodule's size, subtype, and diagnosis of typical intrapulmonary lymph node among lung nodules between ULD and LD CT
- 3) Inter-observer reproducibility for size, subtype and diagnosis of lung nodules in ULD CT
- 4) Influence of subjects characteristics (age, sex, BMI), nodule location, and nodule size on lung nodule detection with ULD CT
- 5) Concordance of emphysema detection, type and distribution between ULD and LD CT
- 6) Concordance of Weston score of coronary calcifications between ULD and LD CT
- 7) Concordance of visual assessment of bronchial thickening, mucoid impaction or dilatation between ULD and LD CT

Eligibility Criteria

Inclusion criteria

- aged 18 years or older
- referred for non-enhanced chest CT for the following indications:
 - lung nodule check-up or follow-up
 - nodular abnormality on chest X ray
 - morphologic assessment of chronic obstructive pulmonary disease (COPD) or emphysema

- asbestos exposure
- assessment before lung radio frequency ablation
- assessment of disease extent of an extra thoracic cancer (in case of iodinated intravenous contrast agent contraindication)
- Check-up before extra-thoracic transplantation (in case of iodinated intravenous contrast agent contraindication).

Exclusion criteria

- Inability to lie down and stay still during the examination
- Inability to hold breath for more than 5 seconds
- Pneumonia in the last 3 months
- Body mass index (BMI) more than 35kg/m²
- Pregnant or breastfeeding women

CT scan acquisitions and reconstructions

The LD and ULD acquisitions are performed on the Revolution CT scanner (GE medical Healthcare, Milwaukee, WI, USA) equipped with the third generation ASIR-V iterative reconstruction. Acquisitions are performed successively in the same CT exam, in the supine position and at suspended full inspiration. Both acquisitions cover the same pulmonary fields from the apex to the costo-diaphragmatic angle, determined on the scout views (2 views).

The LD acquisition is the reference exam for the diagnosis of pulmonary nodules. The acquisition parameters are: spiral CT scanning; 120kVp; automatic modulation of 3D radiation dose (“Smart mA”+ Organ Dose Modulation) with lower bound 100mA, maximal bound 200mA and noise index 10; rotation time: 0.35sec ; modulation 35-70 mAs; pitch = 0.992 :1 and collimation: 80mm. The radiation dose, CTDIvol (volume CT dose index) and DLP (Dose Length Product = CTDIvol x length of exposure) may vary depending on patient attenuation and length of the acquisition. The expected

DLP is between 70 and 200mGy.cm (0.98mSv to 2.8mSv) (the effective dose is calculated by multiplying DLP by a thoracic conversion factor of 0.014 (21)), for an average DLP of 100mGy.cm. The ULD CT acquisition parameters are: spiral CT scanning; 120kVp; fixed tube current of 10mA; rotation time: 0.35s; 3.5 mAs; pitch: 0.992 :1, collimation: 80mm. These parameters are fixed for all patients. The CTDIvol is constant at 0.24mGy. The DLP will depend only on the length of the acquired chest, different for each patient, expected around 10mGy.cm (0.14mSv). The modulation of the mA is deactivated to allow a very low tube current and therefore an ULD acquisition. The ULD acquisition increases the exam time by up to two minutes.

The reconstruction parameters are identical for both acquisitions: slice thickness: 1.25mm; standard filter and lung filter; contiguous 8-mm thickness Maximal Intensity projection (MIP) reconstruction, and iterative reconstruction with different percentages. We use ASIR-V in our study which is the latest generation of iterative reconstruction techniques. It blends hybrid iterative reconstruction and standard filtered back projection. The percentage of ASIR-V represents the amount of iterative reconstruction, from 0% (filtered back projection only) to 100% iterative reconstruction, which modifies image noise and texture. When designing our study, ASIR-V was not yet studied for chest CT. The CT vendor engineers suggested an empirical percentage between 40 up to 100%, depending on radiologist practice and preferences. We decided to test percentages of iterative reconstruction of 50% and 100%. The LD CT images are reconstructed with 50% ASIR-V (LD) and the ULD CT images with 50% (ULD50) and 100% (ULD100) ASIR-V.

The statistical analyses will be performed twice: with ULD50 and ULD100.

For every patient, CTDIvol and DLP are recorded. Effective dose and Size Specific Dose Estimates (SSDE) will be then calculated. Concerning the additional radiation for included patients, our ULD CT protocol has an expected effective dose between 0.10 and 0.20 mSv, which is about 6 to 20 times lower than the LD protocol (which is the usual dose in our institution for this indication), similar to a 2-views CXR, and to 30 days of natural radiation (22). Moreover, total dose of the entire exam (around 1.1 to 3 mSv) is lower than French diagnostic reference level of 6.65mSv.

1
2 247 **Recruitment and intervention**

3
4 248 Patients included in the study are those referred for a diagnostic chest CT without contrast media
5
6 249 injection. On the day of the CT scan, a radiologist checks the eligibility criteria for the study, and
7
8
9 250 informs the patient who signs a participation consent form if he accepts to join the study. The
10
11 251 radiologist then collects the following parameters: height, weight, history of oncology, cardio-
12
13 252 respiratory pathology and exposure to smoking. The patient then undergoes the standard diagnostic
14
15
16 253 LD CT acquisition followed by the ULD acquisition. If, however, the dose of the LD acquisition is
17
18 254 greater than 6.65mSv (French diagnostic reference level), the ULD acquisition is not performed and
19
20 255 the patient is excluded from the data analysis. The patient's participation in the study is completed
21
22
23 256 once he leaves the examination room.

24
25 257 The CT images of the LD acquisition are analysed by the radiologist who gives his medical report for
26
27 258 the patient's medical management. If the number of nodules ≥ 4 mm identified on this acquisition is
28
29
30 259 ≥ 6 in one lung, the patient will be excluded from the data analysis because the analysis of the
31
32 260 outcomes will be too complicated to implement.

33
34 261
35
36 262 **Patient and Public Involvement**

37
38
39 263 Patients or public were not directly involved in the development of the research question. However,
40
41 264 lowering the radiation dose is a rising concern for the patients and for public health. Patients were
42
43 265 also not directly involved in the design, the recruitment and the conduct of this study.

44
45 266 As a regular medical care, the report of the diagnostic LD CT is sent to the prescribing physician, and
46
47
48 267 to the patients at their request. According to French law, patients will be informed of the global results
49
50 268 of the study at their request.

51
52 269
53
54
55 270 **Blind reading of outcomes**

56
57 271 For LD, ULD50 and ULD100 reconstructions, 2 radiologists will independently read all the
58
59 272 radiological parameters. In order to limit the number of exams assessed by each reader, 4 radiologists

split into 2 pairs will participate in the blind reading. Each pair of radiologists (1 junior and 1 senior radiologist) reads the three sets of images for the same patient in a random order.

The term “blind” means that radiologists have neither knowledge of the patient's identity nor access to the results of diagnostic reading. To avoid patient identification, CT acquisitions are anonymized by deleting in the DICOM fields: the name, age and date of birth of the patient; the date and time of the examination and the name of the referring radiologist for the diagnosis. Each patient reconstruction is identified by a random number that differs for each of the two readers. Radiologists never read two series of the same patient consecutively.

Anonymized exams are periodically transmitted to a pair with at least 15 LD, 15 ULD50 and 15 ULD100 reconstructions. The three patient reconstructions are not necessarily given the same day to both radiologists. In addition, the order of presentation is not identical for the two radiologists.

The reading is performed on a diagnostic console (IMPAX software, 6.5.5.3502) (Agfa, Belgium) using Barco MDNC-3121 monitors (Barco, Courtrai, Belgium) and includes mediastinal and parenchymal filter reconstructions for each acquisition. The radiologist is free to adapt the level and width of the window to its reading practice (initial parenchymal window defined by a width of 1500UH and a level of -600UH), and to perform multiplanar reconstructions in the different plans of space. The reading also includes the additional MIP reconstruction for each acquisition, in order to sensitize the detection of nodules (23) (this type of reading from MIP series is performed in clinical routine).

Radiologists identify nodules of longer diameter ≥ 4 mm by locating them with the slice number and the lobe. It is known that each lung has three lobes (right upper lobe, middle lobe, right lower lobe, culmen, lingula, and left lower lobe). Each radiologist completes a reading grid for each reconstruction with all detected nodule characteristics, evaluation of emphysema, coronary calcification and bronchial abnormalities.

The completed grids are given to a Clinical Research Assistant for data entry and identification of discrepancies in identification of nodules between the two radiologists.

1

2 299 We consider that a nodule is the same between the two readers if:

3

4 300 • it is located in the same lobe

5

6 301 • the slice number is identical at ± 5 slices (a nodule will be visible on several successive slices)

7

8 302 • the longest diameter of nodule is the same at ± 2 mm (24)

9

10 303 If these criteria are not respected or if a radiologist identifies one or more nodules in addition to or

11

12 304 less than the second radiologist, a consensus with a third CHUGA senior thoracic radiologist with 27

13

14 305 years of experience is obtained. This third radiologist is not part of the reading pairs. The consensus

15

16 306 is made from anonymized reconstructions and the reconstructions of the same patient are not

17

18 307 processed successively.

19

20 308 Besides, for every reconstruction is recorded:

21

22 309 - noise by measuring standard deviation in a region of interest placed in the tracheal air above

23

24 310 the carina,

25

26 311 - shape of the trachea which indicates inspiration degree,

27

28 312 - subjective image quality on a 3-point scale.

29

30 313

31

32 314 **Data monitoring**

33

34 315 All data is monitored by Grenoble-Alpes University Hospital (trial sponsor), in order to verify that

35

36 316 for every patient enrolled there is a signed consent form and that the inclusion and exclusion criteria

37

38 317 are respected. In addition all data collected in the case report form of every enrolled patient are

39

40 318 verified.

41

42 319

43

44 320 **Sample size**

45

46 321 With a 90% power, to have a sensitivity of detection of nodules with the ULD CT to 90% with a

47

48 322 confidence interval to $\pm 10\%$, it would be necessary to analyze 124 nodules. According to a

49

50 323 retrospective analysis of patients with indication of pulmonary nodule CT made at CHUGA, out of

51

52 324 420 patients per year with this indication, 210 present pulmonary nodules with a total of about 400

53

nodules. It should therefore include about 140 patients to have 124 nodules to be analyzed. Considering a 5% potential loss to follow-up or withdrawal of consent, the actual number of subjects to include is 147 in total. To this are added three potential patients who could be secondarily excluded from the study for a number of nodules ≥ 6 in one of the lungs. The total number of patients to include is 150. The sample size calculations were carried out using R software version 3.1.0 (library MKmisc, function power.diagnostic.test) (25, 26, 27).

Statistical analysis

In this non-randomized study where each patient is his own control, the threshold $p < 0.05$ will be taken into account to define the significance of the statistical tests. Analyses will be carried out in accordance with good statistical analysis practices after freezing of the database and will be carried out with the software R (version $\geq 3.1.0$).

The normality of the quantitative parameters will be determined by the Shapiro-Wilks test or by graphical verification of the symmetry of the distribution. When the normality of the distribution of such a parameter has been demonstrated, it will be described by its mean and its standard deviation. Otherwise it will be described by its median, the 25th and the 75th percentile. The qualitative parameters will be expressed in number and percentage.

For the main objective, the sensitivity of the ULD CT (compared to the LD CT) for the detection of nodules will be calculated and accompanied by a 95% confidence interval. For secondary objective 1, the number of TP, FP, TN, FN, PPV, NPV and Sp of the ULD CT (compared to LD CT) will be calculated. For secondary objectives 2, 5, 6 and 7, the concordance of the qualitative variables will be evaluated using the kappa coefficient. The concordance of the quantitative variables will be evaluated using Lin's concordance coefficient. For each coefficient, the 95% confidence interval will be given. For secondary objective 3, inter-observer reproducibility for qualitative variables will be evaluated using the kappa coefficient. It will be evaluated, for the quantitative variables, using the ICC (intra class coefficient). For each coefficient, the 95% confidence interval will be given. For

secondary objective 4, a logistic regression model will be implemented. The variable to be explained will be the result of detecting each nodule in ULD CT compared to the LD CT (0 = good detection / 1 = bad detection). The explanatory variables will be the age, sex and BMI of the patient, the location (lobe) and the size of the nodule. The size of the nodule can be used as a qualitative variable (<5mm, 5-10mm, > 10mm).

An interim analysis including the analysis of the primary endpoint will be performed after inclusion of the first 50 patients. This interim analysis will aim to: decide whether to continue or stop the study for futility and readjust the number of patients if necessary (if the characteristics of the patients included do not correspond to those initially planned (too many patients without nodules ≥ 4 mm)). In order to maintain an overall threshold of 5% in the final analysis, the interim analysis will be carried out with a threshold of 0.1%. The results of the interim analysis will be taken into account by the steering committee to propose modifications to the analysis plan. For this interim analysis, data from the confrontation between the two radiologists will be used.

Limitations

First limitation of our protocol is that we do not have a true screening population because there is no organized lung cancer screening program in our country yet. Therefore, our study population corresponds to patients routinely referred for lung nodule checkup or follow up instead of a risk-factor based population.

Another limitation is that ULD CT is easily recognizable as the image noise is increased as compared to LD CT, as well as ULD 50 and ULD 100 are possible to distinguish for an experienced radiologist. As a consequence, readers were not blinded for these, but for patient name, sex, age, clinical status, and CT report.

Recall bias is limited by a randomized order of presentation and cutting into several reading sessions.

Although we wanted to have a “western population”, we decided not to include obese patients with a BMI > 35, because ULD CT are of poorer quality, due to the need of more radiation-exposure to

produce acceptable images. Vardhanabhuti and al. recently found a loss of nodule detection with iterative reconstructed CT scanners at an effective dose of $0.14 \pm 0.01 \text{ mSv}$ for obese patients with BMI > 38 (28).

We decided to test percentage of 50 and 100% of ASIR-V. Tang and al. tested ASIR-V from 10 to 100% in non-enhanced chest and showed ASIR-V has greater potential in reducing image noise and artifacts and maintaining image sharpness when compared to ASIR, and 60% ASIR-V had the highest image quality combining both the objective and subjective evaluation of images (29). This finding, although occurring after the design of our study is close to our chosen 50% level of ASIR-V.

Finally, our study has been conceived before the recommendations of the EU Position statement published at the end of 2017 (30). Therefore, we measured manually the nodules instead of using computerized volumetry.

FUNDING

This trial is funded by the Delegation to Clinical Research and Innovation (DRCI) of Grenoble-Alpes University Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

AUTHOR CONTRIBUTIONS

M. Ludwig is the corresponding author and contributed to the conception of the study, to the inclusion of patients, to the blind reading of outcomes and to the drafting of the manuscript.

E. Chipon contributed to the conception of the study, to the drafting of the manuscript, and is responsible for data management and its integrity.

J. Cohen contributed to the conception of the study, to the inclusion of patients, to the blind reading of outcomes and to the revision of the manuscript.

1
2 402 E. Reymond contributed to the inclusion of patients, to the blind reading of outcomes and to the
3
4 403 revision of the manuscript.
5
6 404 M. Medici contributed to the design and application of statistical analysis, and to the drafting of the
7
8
9 405 manuscript.
10
11 406 A. Cole contributed to the blind reading of outcomes and to the revision of the manuscript.
12
13 407 A. Moreau Gaudry contributed to the conception of the study and to the revision of the manuscript.
14
15
16 408 G R Ferretti is the principal investigator of the study and contributed to the conception of the work,
17
18 409 to the inclusion of patients, to the blind consensus of outcomes and to the revision of the manuscript.
19
20 410 All authors approved the final manuscript and agreed to be accountable for all aspects of the work.
21
22
23 411

24
25 412 **COMPETING INTERESTS**

26
27 413 The authors declare that they have no competing interests
28
29
30 414

31
32 415 **CONSENT FOR PUBLICATION**

33
34 416 Not applicable
35
36
37 417

38
39 418 **ETHICS AND DISSEMINATION**

40
41 419 This trial is registered on the ClinicalTrials.gov database (reference NCT03305978) (see
42
43 420 supplementary file “trial registration data set”), and was approved by the relevant ethical committee
44
45
46 421 (Comité de Protection des Personnes, CPP sud-est VI, France, 07/07/2017, CPP Reference: AU1342).
47
48 422 The Protocol version is N°1.0- Date: May 4th 2017
49
50 423
51
52 424 All patients sign a consent form before being enrolled in the trial, in accordance with the Declaration
53
54
55 425 of Helsinki II.
56
57 426 Once the statistical report is finalized, we plan to publish our results in an international scientific
58
59
60 427 journal and present them in national and international congresses.

DATA STATEMENT

Legal restrictions (French personal data laws) prohibit the authors from making the minimal data set publicly available. These data are available upon request.

ACKNOWLEDGEMENTS

The authors thank Alexandre Rey and Pierre Pittet for their help to collect and prepare data, Tarek Ittobane for data monitoring, Dr A. Jankowski for the inclusion of patients, and Laura Cotarla for English proofreading.

REFERENCES

1. Globocan : Lung Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx)
2. National Lung Screening Trial Research Team, Denise R. Aberle, Amanda M. Adams, Christine D. Berg, William C. Black, Jonathan D. Clapp, Richard M. Fagerstrom, et al.
“Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening.” *The New England Journal of Medicine* 365, no. 5 (August 4, 2011): 395–409.
doi:10.1056/NEJMoa1102873
3. Yousaf-Khan U, van der Aalst C, de Jong PA, et al.”Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval.” *Thorax* 2017;72:48-56. 10.1136/thoraxjnl-2016-208655
4. Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation and National Research Council. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, D.C: The National Academies Press; 2006

5. Kubo T, Ohno Y, Seo JB, Yamashiro T, Kalender WA, Lee CH, et al. "Securing safe and informative thoracic CT examinations-Progress of radiation dose reduction techniques". *Eur J Radiol*. 2017 Jan;86:313–9.
6. Kim, Yookyung, Yoon Kyung Kim, Bo Eun Lee, SeokJeong Lee, YonJuRyu, Jin Hwa Lee, and Jung Hyun Chang. "Ultra-Low-Dose CT of the Thorax Using Iterative Reconstruction: Evaluation of Image Quality and Radiation Dose Reduction." *AJR. American Journal of Roentgenology* 204, no. 6 (June 2015): 1197–1202. doi:10.2214/AJR.14.13629.
7. Vardhanabhuti, Varut, Robert J. Loader, Grant R. Mitchell, Richard D. Riordan, and Carl A. Roobottom. "Image Quality Assessment of Standard- and Low-Dose Chest CT Using Filtered Back Projection, Adaptive Statistical Iterative Reconstruction, and Novel Model-Based Iterative Reconstruction Algorithms." *AJR. American Journal of Roentgenology* 200, no. 3 (March 2013): 545–52. doi:10.2214/AJR.12.9424.
8. Ichikawa, Yasutaka, Kakuya Kitagawa, Naoki Nagasawa, Shuichi Murashima, and Hajime Sakuma. "CT of the Chest with Model-Based, Fully Iterative Reconstruction: Comparison with Adaptive Statistical Iterative Reconstruction." *BMC Medical Imaging* 13 (2013): 27. doi:10.1186/1471-2342-13-27.
9. Padole, Atul, Sarabjeet Singh, Jeanne B. Ackman, Carol Wu, Synho Do, Sarvenaz Pourjabbar, Ranish Deedar Ali Khawaja, et al. "Submillisievert Chest CT with Filtered Back Projection and Iterative Reconstruction Techniques." *AJR. American Journal of Roentgenology* 203, no. 4 (October 2014): 772–81. doi:10.2214/AJR.13.12312.
10. Montet, Xavier, Anne-Lise Hachulla, Angeliki Neroladaki, Frederic Lador, Thierry Rochat, Diomidis Botsikas, and Christoph D. Becker. "Image Quality of Low mA CT Pulmonary Angiography Reconstructed with Model Based Iterative Reconstruction versus Standard CT Pulmonary Angiography Reconstructed with Filtered Back Projection: An Equivalency Trial." *EuropeanRadiology* 25, no. 6 (June 2015): 1665–71. doi:10.1007/s00330-014-3563-5.

11. Yoon, Hyun Jung, Myung Jin Chung, Hye Sun Hwang, Jung Won Moon, and Kyung Soo Lee. “Adaptive Statistical Iterative Reconstruction-Applied Ultra-Low-Dose CT with Radiography-Comparable Radiation Dose: Usefulness for Lung Nodule Detection.” *Korean Journal of Radiology* 16, no. 5 (October 2015): 1132–41. doi:10.3348/kjr.2015.16.5.1132
12. Sui, Xin, Felix G. Meinel, Wei Song, Xiaoli Xu, Zixing Wang, Yuyan Wang, Zhengyu Jin, Jiahong Chen, Rozemarijn Vliegenthart, and U. Joseph Schoepf. “Detection and Size Measurements of Pulmonary Nodules in Ultra-Low-Dose CT with Iterative Reconstruction Compared to Low Dose CT.” *European Journal of Radiology* 85, no. 3 (March 2016): 564–70. doi:10.1016/j.ejrad.2015.12.013
13. Nagatani Y, Takahashi M, Murata K, Ikeda M, Yamashiro T, Miyara T, Koyama H, Koyama M, Sato Y, Moriya H, et al “Lung nodule detection performance in five observers on computed tomography (CT) with adaptive iterative dose reduction using three-dimensional processing (AIDR 3D) in a Japanese multicenter study: Comparison between ultra-low-dose CT and low-dose CT by receiver-operating characteristic analysis”. *Eur J Radiol.* 2015 Jul; 84(7):1401-12. Epub 2015 Apr 2
14. Huber, Adrian, Julia Landau, Lukas Ebner, Yanik Bütikofer, Lars Leidolt, Barbara Brela, Michelle May, Johannes Heverhagen, and Andreas Christe. “Performance of Ultralow-Dose CT with Iterative Reconstruction in Lung Cancer Screening: Limiting Radiation Exposure to the Equivalent of Conventional Chest X-Ray Imaging.” *EuropeanRadiology*, January 26, 2016. doi:10.1007/s00330-015-4192-3
15. Messerli M, Kluckert T, Knitel M, Wälti S, Desbiolles L, Rengier F, et al. “Ultralow dose CT for pulmonary nodule detection with chest x-ray equivalent dose - a prospective intra-individual comparative study”. *EurRadiol.* 2017 Aug;27(8):3290–9.
16. Neroladaki, Angeliki, Diomidis Botsikas, Sana Boudabbous, Christoph D. Becker, and Xavier Montet. “Computed Tomography of the Chest with Model-Based Iterative Reconstruction

- Using a Radiation Exposure Similar to Chest X-Ray Examination: Preliminary Observations.”
European Radiology 23, no. 2 (February 2013): 360–66. doi:10.1007/s00330-012-2627-7.
17. De Marco P, Origgi D. “New adaptive statistical iterative reconstruction ASiR-V: Assessment of noise performance in comparison to ASiR”. *J Appl Clin Med Phys*. 2018 Mar;19(2):275-286. doi: 10.1002/acm2.12253. Epub 2018 Jan 24. PubMed PMID: 29363260; PubMed Central PMCID: PMC5849834
18. Gierada DS, Pinsky P, Nath H, Chiles C, Duan F, Aberle DR. “Projected outcomes using different nodule sizes to define a positive CT lung cancer screening examination”. *J Natl Cancer Inst*. 2014;106:dju284
19. Bankier A, MacMahon H, Goo JM, et al. Recommendations for Measuring Pulmonary Nodules at CT: A Statement from the Fleischner Society. *Radiology* 2017;285:584-600 doi:10.1148/radiol.2017162894
20. Ahn MI, Gleeson TG, Chan IH et-al. “Perifissural nodules seen at CT screening for lung cancer”. *Radiology*. 2010;254 (3): 949-56. doi:10.1148/radiol.09090031
21. Task Group on Control of Radiation Dose in Computed Tomography. “Managing Patient Dose in Computed Tomography. A Report of the International Commission on Radiological Protection.” *Annals of the ICRP* 30, no. 4 (2000): 7–45
22. Exposition de la population française aux rayonnements ionisants liée aux actes de diagnostic médical en 2012. Rapport IRSN PRP-HOM N°2014-6
23. Jankowski, A., T. Martinelli, J. F. Timsit, C. Brambilla, F. Thony, M. Coulomb, and G. Ferretti. “Pulmonary Nodule Detection on MDCT Images: Evaluation of Diagnostic Performance Using Thin Axial Images, Maximum Intensity Projections, and Computer-Assisted Detection.” *European Radiology* 17, no. 12 (December 2007): 3148–56. doi:10.1007/s00330-007-0727-6.

24. Revel MP, Bissery A, Bienvenu M, Aycard L, Lefort C, Fria G. Are two-dimensional CT measurements of small noncalcified pulmonary nodules reliable? *Radiology*. 2004 May;231(2):453-8. PubMed PMID: 15128990.
25. A. Flahault, M. Cadilhac, and G. Thomas (2005). Sample size calculation should be performed for design accuracy in diagnostic test studies. *Journal of Clinical Epidemiology*, 58(8):859-862.
26. H. Chu and S.R. Cole (2007). Sample size calculation using exact methods in diagnostic test studies. *Journal of Clinical Epidemiology*, 60(11):1201-1202.
27. M.R. Chernick and C.Y. Liu (2002). The saw-toothed behavior of power versus sample size and software solutions: single binomial proportion using exact methods. *Am Stat*, 56:149-155.
28. Vardhanabhuti V, Pang CL, Tenant S, Taylor J, Hyde C, Roobottom C. "Prospective intra-individual comparison of standard dose versus reduced-dose thoracic CT using hybrid and pure iterative reconstruction in a follow-up cohort of pulmonary nodules-Effect of detectability of pulmonary nodules with lowering dose based on nodule size, type and body mass index". *Eur J Radiol*. 2017 Jun;91:130-141. doi: 10.1016/j.ejrad.2017.04.006
29. Tang H, Yu N, Jia Y, Yu Y, Duan H, Han D, et al. "Assessment of noise reduction potential and image quality improvement of a new generation adaptive statistical iterative reconstruction (ASIR-V) in chest CT". *Br J Radiol*. 2018 Jan;91(1081):20170521
30. Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. *Lancet Oncol* 2017;18: e754–66. [http://dx.doi.org/10.1016/S1470-2045\(17\)30861-6](http://dx.doi.org/10.1016/S1470-2045(17)30861-6)

FIGURE 1 legend:


Study Flow chart. ASIR-V[®], adaptive statistical iterative reconstruction-Véo (GE medical Healthcare, Milwaukee, WI, USA); CT, computed tomography; LD, low dose; LD50, low

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

dose CT with 50% ASIR-V reconstruction; ULD, ultra-low dose; ULD50, ultra-low dose CT
with 50% ASIR-V reconstruction, ULD 100, ultra-low dose CT with 100% ASIR-V
reconstruction

For peer review only

Figure 1



Study Flow chart. ASIR-V ®, adaptive statistical iterative reconstruction-Véo (GE medical Healthcare, Milwaukee, WI, USA); CT, computed tomography; LD, low dose; LD50, low dose CT with 50% ASIR-V reconstruction; ULD, ultra-low dose; ULD50, ultra-low dose CT with 50% ASIR-V reconstruction, ULD 100, ultra-low dose CT with 100% ASIR-V reconstruction.

210x297mm (300 x 300 DPI)

Trial registration data set :

Primary registry and trial identifying number	ClinicalTrials.gov NCT03305978
Date of registration in primary registry	September 26, 2017
Secondary identifying numbers	38RC17.132
Source(s) of monetary or material support	University Hospital, Grenoble
Primary sponsor	University Hospital, Grenoble
Secondary sponsor(s)	French Thoracic Imaging Society
Contact for public queries	Emilie CHIPON, PhD, +33476767313, echipon@chu-grenoble.fr
Contact for scientific queries	Gilbert FERRETTI, MD PhD, +3376767313, gferretti@chu-grenoble.fr
Public title	Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan.
Scientific title	Detection of Pulmonary Nodules: Comparison of Ultra-low-dose Chest CT (Approaching a Two Views Chest X-ray Radiation) and Standard Low Dose CT. A Monocentric, Prospective, Non-randomized, Comparative, Open-label Study With Blind Reading of the Judgment Criteria
Country of recruitment	France
Health condition(s) or problem(s) studied	Lung cancer screening, radiation exposure
Intervention(s)	<p><u>Device: Ultra low dose chest CT</u> An additional ultra low dose CT row is performed for every subject besides standard diagnostic low dose chest CT. Other Name: Revolution CT (GE Healthcare) 442507CN0, equipped with ASIR V</p> <p><u>Device: Low dose chest CT</u> standard diagnostic low dose chest CT Other Name: Revolution CT (GE Healthcare)</p>
Key inclusion and exclusion criteria	<p>Ages eligible for study: ≥ 18 years Sexes eligible for study: both Accepts healthy volunteers: no</p> <p><u>Inclusion criteria :</u> Patients referred for non enhanced chest CT for following indications :</p> <ul style="list-style-type: none"> - lung nodule search or control - nodular abnormality on chest X ray - statement of COPD or emphysema - asbestos exposure - nodule localization before radio frequency ablation - assessment of disease extent of an extra thoracic cancer (in case of iodinated intravenous contrast agent contraindication) - statement before extrathoracic transplantation (in case of iodinated intravenous contrast agent contraindication) <p>Affiliated with the french social security Who signed consent</p> <p><u>Exclusion criteria :</u> Inability to lie down and stay still during the examination Inability to hold breath more than 5 seconds Pneumonia in the last 3 months Body mass index more than 35kg/m² exclusion period of another interventionnal study</p>

	referred for articles L1121-5 to L1121-8 of french public health code Pregnant or breastfeeding women
Study type	<p>Interventional</p> <p><u>Allocation</u>: Non-Randomized <u>Intervention Model</u>: Sequential Assignment <u>Intervention Model Description</u>: Major Patient Addressed for Thoracic CT without Injection of Contrast <u>Masking</u>: Single (Outcomes Assessor) <u>Masking Description</u>: blinding evaluation of criteria</p> <p><u>Primary purpose</u>: diagnostic</p>
Date of first enrolment	October 3, 2017
Target sample size	150
Recruitment status	Recruiting
Primary outcome(s)	<p>Ultra low dose CT lung nodule detection sensibility [Time Frame: 22 months]</p> <p>Detection rate (%) of ≥ 4mm lung nodules in ultra low dose chest CT versus standard low</p>
Key secondary outcomes	<ul style="list-style-type: none"> - Ultra low dose CT diagnostic performances of lung nodule detection [Time Frame: 22 months] :true positives, false positives, true negatives, false negatives, positive predictive value, negative predictive value, specificity, of ≥ 4mm lung nodules detection within ultra low dose chest CT versus standard low dose chest CT - Concordance of ≥ 4mm lung nodules characteristics between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : comparison of size, density, type (true nodule or intrapulmonary ganglion) of ≥ 4mm lung nodule between ultra low dose and standard low dose chest CT - Ultra low dose CT inter-observer reproducibility [Time Frame: 22 months] : inter observer reproducibility for size, density and type of ≥ 4mm lung nodule detected in ultra low dose CT - Influence of subjects characteristics, nodule location, and nodule size on detection between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : analysis of subjects characteristics (age, gender, body mass index), ≥ 4mm nodule location, and ≥ 4 mm nodule size on detection between ultra low dose and standard low dose chest CT - Concordance of emphysema characteristics between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : comparison of emphysema detection, type (centrilobular, paraseptal, panlobular, bullous) and distribution between ultra low dose and standard low dose chest CT - Concordance of coronary calcification detection and quantification between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : Comparison of Weston scores between ultra low dose and standard low dose chest CT - Concordance of bronchial abnormalities evaluation between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : comparison of detection of bronchial thickening or dilatation between ultra low dose and standard low dose chest CT
Ethics Review	approved by the relevant ethical committee (Comité de Protection des Personnes, CPP Sud-Est VI, France, CPP Reference: AU1342), on July 7, 2017

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-207

			Page Number
Reporting Item			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	17
Protocol version	#3	Date and version identifier	18
Funding	#4	Sources and types of financial, material, and other support	16
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1;16
Roles and responsibilities:	#5b	Name and contact information for the trial sponsor	2

1	sponsor contact			
2	information			
3				
4	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	16
5	responsibilities:		collection, management, analysis, and interpretation of	
6	sponsor and funder		data; writing of the report; and the decision to submit the	
7			report for publication, including whether they will have	
8			ultimate authority over any of these activities	
9				
10				
11				
12	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	n/a
13	responsibilities:		centre, steering committee, endpoint adjudication	
14	committees		committee, data management team, and other individuals or	
15			groups overseeing the trial, if applicable (see Item 21a for	
16			data monitoring committee)	
17				
18				
19				
20	Background and	#6a	Description of research question and justification for	5
21	rationale		undertaking the trial, including summary of relevant studies	
22			(published and unpublished) examining benefits and harms	
23			for each intervention	
24				
25				
26				
27	Background and	#6b	Explanation for choice of comparators	6
28	rationale: choice of			
29	comparators			
30				
31				
32	Objectives	#7	Specific objectives or hypotheses	7
33				
34				
35	Trial design	#8	Description of trial design including type of trial (eg, parallel	7
36			group, crossover, factorial, single group), allocation ratio,	
37			and framework (eg, superiority, equivalence, non-inferiority,	
38			exploratory)	
39				
40				
41				
42	Study setting	#9	Description of study settings (eg, community clinic,	7
43			academic hospital) and list of countries where data will be	
44			collected. Reference to where list of study sites can be	
45			obtained	
46				
47				
48	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	8
49			eligibility criteria for study centres and individuals who will	
50			perform the interventions (eg, surgeons, psychotherapists)	
51				
52				
53				
54	Interventions:	#11a	Interventions for each group with sufficient detail to allow	10
55	description		replication, including how and when they will be	
56			administered	
57				
58				
59				
60				

1	Interventions:	#11b	Criteria for discontinuing or modifying allocated	11
2	modifications		interventions for a given trial participant (eg, drug dose	
3			change in response to harms, participant request, or	
4			improving / worsening disease)	
5				
6				
7				
8	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	n/a
9	adherence		and any procedures for monitoring adherence (eg, drug	
10			tablet return; laboratory tests)	
11				
12				
13	Interventions:	#11d	Relevant concomitant care and interventions that are	n/a
14	concomitant care		permitted or prohibited during the trial	
15				
16				
17	Outcomes	#12	Primary, secondary, and other outcomes, including the	8
18			specific measurement variable (eg, systolic blood pressure),	
19			analysis metric (eg, change from baseline, final value, time	
20			to event), method of aggregation (eg, median, proportion),	
21			and time point for each outcome. Explanation of the clinical	
22			relevance of chosen efficacy and harm outcomes is strongly	
23			recommended	
24				
25				
26				
27				
28	Participant timeline	#13	Time schedule of enrolment, interventions (including any	7
29			run-ins and washouts), assessments, and visits for	
30			participants. A schematic diagram is highly recommended	
31			(see Figure)	
32				
33				
34				
35	Sample size	#14	Estimated number of participants needed to achieve study	13
36			objectives and how it was determined, including clinical and	
37			statistical assumptions supporting any sample size	
38			calculations	
39				
40				
41				
42	Recruitment	#15	Strategies for achieving adequate participant enrolment to	11
43			reach target sample size	
44				
45				
46	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	n/a
47	generation		computer-generated random numbers), and list of any	
48			factors for stratification. To reduce predictability of a random	
49			sequence, details of any planned restriction (eg, blocking)	
50			should be provided in a separate document that is	
51			unavailable to those who enrol participants or assign	
52			interventions	
53				
54				
55				
56				
57	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	n/a
58	concealment		central telephone; sequentially numbered, opaque, sealed	
59				
60				

mechanism		envelopes), describing any steps to conceal the sequence until interventions are assigned	
Allocation: implementation	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	n/a
Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	11
Blinding (masking): emergency unblinding	#17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n/a
Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	12
Data collection plan: retention	#18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	n/a
Data management	#19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	13
Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	13
Statistics: additional analyses	#20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	14
Statistics: analysis population and missing data	#20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	13

1	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	13
2	formal committee		of its role and reporting structure; statement of whether it is	
3			independent from the sponsor and competing interests; and	
4			reference to where further details about its charter can be	
5			found, if not in the protocol. Alternatively, an explanation of	
6			why a DMC is not needed	
7				
8				
9				
10				
11	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	14
12	interim analysis		including who will have access to these interim results and	
13			make the final decision to terminate the trial	
14				
15				
16	Harms	#22	Plans for collecting, assessing, reporting, and managing	n/a
17			solicited and spontaneously reported adverse events and	
18			other unintended effects of trial interventions or trial conduct	
19				
20				
21	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	n/a
22			and whether the process will be independent from	
23			investigators and the sponsor	
24				
25				
26				
27	Research ethics	#24	Plans for seeking research ethics committee / institutional	16
28	approval		review board (REC / IRB) approval	
29				
30				
31	Protocol	#25	Plans for communicating important protocol modifications	n/a
32	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
33			relevant parties (eg, investigators, REC / IRBs, trial	
34			participants, trial registries, journals, regulators)	
35				
36				
37	Consent or assent	#26a	Who will obtain informed consent or assent from potential	16
38			trial participants or authorised surrogates, and how (see	
39			Item 32)	
40				
41				
42				
43	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
44	ancillary studies		participant data and biological specimens in ancillary	
45			studies, if applicable	
46				
47				
48	Confidentiality	#27	How personal information about potential and enrolled	n/a
49			participants will be collected, shared, and maintained in	
50			order to protect confidentiality before, during, and after the	
51			trial	
52				
53				
54				
55	Declaration of	#28	Financial and other competing interests for principal	16
56	interests		investigators for the overall trial and each study site	
57				
58				
59	Data access	#29	Statement of who will have access to the final trial dataset,	19
60				

		and disclosure of contractual agreements that limit such access for investigators	
Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	16
Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	n/a
Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a

The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 23. July 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Detection of pulmonary nodules: a clinical study protocol to compare ultra-low dose chest CT and standard low-dose CT using ASIR-V.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025661.R3
Article Type:	Protocol
Date Submitted by the Author:	20-Jun-2019
Complete List of Authors:	Ludwig, Marie; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine Chipon, Emilie; INSERM, CIC 1406; Centre Hospitalier Universitaire Grenoble Alpes, pôle recherche Cohen, Julien; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine Reymond, Emilie; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie Medici, Maud; INSERM, CIC 1406; Centre Hospitalier Universitaire Grenoble Alpes, pôle recherche Cole, Anthony; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine Moreau Gaudry, Alexandre; INSERM, CIC 1406; Centre Hospitalier Universitaire Grenoble Alpes, pôle recherche Ferretti, Gilbert; Centre Hospitalier Universitaire Grenoble Alpes, service de radiologie et imagerie médicale, pôle imagerie; Université Grenoble Alpes Faculté de Médecine
Primary Subject Heading:	Radiology and imaging
Secondary Subject Heading:	Oncology, Respiratory medicine, Smoking and tobacco
Keywords:	low dose computed tomography, ultra low dose computed tomography, pulmonary nodule, lung cancer screening, iterative reconstruction

SCHOLARONE™
Manuscripts

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Detection of pulmonary nodules: a clinical study protocol to compare ultra-low dose chest CT and standard low-dose CT using ASIR-V.

M Ludwig, E Chipon, J Cohen, E Reymond, M Medici, A. Colé, A.Moreau-Gaudry, G R Ferretti

Corresponding author:

Marie Ludwig

Service de radiologie diagnostique et thérapeutique

CHU Grenoble Alpes

CS 10217

38043 Grenoble CEDEX 9

France

mludwig@chu-grenoble.fr

+33 476769290

Affiliations E. Chipon /M.Medici

INSERM, CIC 1406, F-38000 Grenoble, France

Université Grenoble-Alpes, CIC 1406, F-38000 Grenoble, France

CHU Grenoble-Alpes, Pôle Recherche, F-38000 Grenoble, France

Affiliations A.Moreau-Gaudry

Université Grenoble-Alpes, CNRS, Grenoble INP, TIMC-IMAG, F-38000 Grenoble, France

INSERM, CIC 1406, F-38000 Grenoble, France

CHU Grenoble-Alpes, Pôle Recherche, F-38000 Grenoble, France

CHU Grenoble-Alpes, Pôle Santé Publique, F-38000 Grenoble, France

Affiliations G.R. Ferretti, M Ludwig, J Cohen, E Reymond, A.Cole

Université Grenoble-Alpes, F-38000 Grenoble, France

Service de radiologie diagnostique et thérapeutique, CHU Grenoble Alpes, CS 10217, 38043
Grenoble CEDEX 9, France

28

Sponsor:

Delegation to Clinical Research and Innovation (DRCI) of Grenoble-Alpes University Hospital
CHU Grenoble-Alpes, Pôle Recherche, F-38000 Grenoble, France
+33476767575

33

34

35

KEYWORDS

Low dose computed tomography, Ultra low-dose computed tomography, pulmonary nodule, Lung
cancer screening, iterative reconstruction

39

40

Word count, excluding title page, abstract, article summary, references, figures, tables, and
acknowledgements : 4047

43

44

45

46

47

1
2 48 **ABSTRACT**

3
4 49 Introduction:

5
6 50 Lung cancer screening in individuals at risk has been recommended by various scientific institutions.
7
8 51 One of the main concerns for CT screening is repeated radiation exposure, with the risk of inducing
9
10 52 malignancies in healthy individuals. Therefore, lowering the radiation dose is one of the main
11
12 53 objectives for radiologists. The aim of this study is to demonstrate that an ultra-low dose (ULD) chest
13
14 54 CT protocol, using recently introduced hybrid iterative reconstruction (ASiR-V, GE medical
15
16 55 Healthcare, Milwaukee, WI, USA), is as performant as a standard “low dose” (LD) CT to detect non
17
18 56 calcified lung nodules $\geq 4\text{mm}$.

19
20
21
22 57 Methods and analysis:

23
24 58 The total number of patients to include is 150. Those are referred for non-enhanced chest CT for
25
26 59 detection or follow-up of lung nodule and will undergo an additional unenhanced ULD CT
27
28 60 acquisition, the dose of which is on average 10 times lower than the conventional LD acquisition.
29
30 61 Total dose of the entire exam (LD + ULD) is lower than the French diagnostic reference level for a
31
32 62 chest CT (6.65 milliSievert). ULD CT images will be reconstructed with 50% and 100% ASIR-V,
33
34 63 and LD CT with 50%. The 3 sets of images will be read in random order by two pair of radiologists,
35
36 64 in a blind test, where patient identification and study outcomes are concealed. Detection rate
37
38 65 (sensitivity) is the primary outcome. Secondary outcomes will include concordance of nodule
39
40 66 characteristics; inter-observer reproducibility; influence of subjects’ characteristics, nodule location,
41
42 67 and nodule size; and concordance of emphysema, coronary calcifications evaluated by visual scoring
43
44 68 and bronchial alterations between LD and ULD CT. In case of discordance, a third radiologist will
45
46 69 arbitrate.

47
48
49
50 70 Ethics and dissemination:

51
52 71 The study was approved by the relevant ethical committee. Each study participant will sign an
53
54 72 informed consent form.

55
56 73 **Trial registration number:** *Clinicaltrials.gov* NCT03305978

ARTICLE SUMMARY:

STRENGTHS AND LIMITATIONS OF THIS STUDY

- We will evaluate the sensitivity of an ultra-low dose CT, delivering 10 times less radiation than conventional low-dose CT, to detect lung nodules, in a French population of 150 patients referred for lung nodule check-up or follow-up.
- We will use a recently introduced hybrid iterative reconstruction (ASiR-V) and different levels of ASiR-V will be assessed
- Nodules characteristics will be analyzed in particular the diagnosis of intrapulmonary lymph node, which is a benign lesion.
- Patients with morbid obesity (BMI>35) will not be included as image quality of ultra-low dose CT is not acceptable for those morphotypes.
- Readers will be aware of the type of CT acquisition (LD and ULD) and reconstruction, because they are easily recognizable due to the different level of image noise.

1
2 91 **INTRODUCTION**

3
4 92 Lung cancer is the deadliest cancer in the world (1), mainly due to the fact that it is often diagnosed
5
6 93 at advanced stages that are not surgically curable. The current challenge is therefore to detect lung
7
8
9 94 cancer at early asymptomatic stages. Risk factors such as smoking and occupational exposure (mainly
10
11 95 asbestos, silica, arsenic, chromium, iron, coal, ionising radiation) are well known and enable to define
12
13 96 the target population for such programs.

14
15
16 97 The National Lung Screening Trial (NLST) was the first study to show that a low dose (LD) (average
17
18 98 effective dose of 1.5mSv) computed tomography (CT) lung cancer screening reduced specific death
19
20 99 by 20% (95% CI, 6.8 to 26.7; P=0.004) as compared with chest X Ray (CXR) screening (single-view
21
22
23 100 posteroanterior) in actual or former smokers (>30 pack years) patients between 55 and 74 years old
24
25 101 (2).

26
27 102 Other lung cancer screening studies are still in progress in Europe, such as the NELSON study in
28
29
30 103 Belgium and the Netherlands, the results of which are expected to be reported soon (3)

31
32 104 However, the drawback of using LD CT at such doses (<1.5 millisievert (mSv)) is that even though
33
34 105 irradiating less than standard chest CT, the radiation exposure is still on average 10 times higher than
35
36 106 a 2 views CXR, and may be a risk for induced malignancies in itself. (4)

37
38
39 107 In this context, great efforts are currently being made by CT manufacturers to reduce the dose and
40
41 108 maintain diagnostic quality. Technologies such as automated exposure control, lower tube current
42
43 109 and iterative reconstruction (5), were recently introduced, enabling further dose decrease for chest
44
45
46 110 CTs, and the concept of “ultra-low dose (ULD) CT” (or submillisievert CT), which delivers a
47
48 111 radiation dose approaching that of 2 CXR views at the cost of a slight deterioration of the image
49
50 112 quality (6). Among these technological advances, the most significant is probably the new iterative
51
52
53 113 reconstruction whether full iterative or hybrid. (7,8,9,10)

54
55 114 Promising results have been published for lung nodule detection with ULD CT (11,12,13). However,
56
57 115 these studies were conducted on Asian populations, which may have different morphotypes compared
58
59
60 116 to Caucasian populations.

Huber and al. performed a phantom study comparing standard, LD and ULD CT for detection of pulmonary nodules. When compared to standard CT, the detection rate was 95.5% for LD CT (1.76 mSv), and 93.3% for ULD CT (0.13mSv), increasing at 97.5% when adding computer aided diagnosis and maximal intensity projection (14).

Since we started to design our study protocol, Messerli and al. published a study including 202 patients referred for any clinically indicated chest CT. 91.2% nodules were detected using ULD CT (0.13 \pm 0.01mSv) as compared to LD CT (1.8 \pm 0.7 mSv). Sensitivity was significantly higher for larger nodule diameter, lower BMI patients, lower image noise and for solid and calcified nodules (15).

Neroladaki and al. showed the same number of detected nodules between an ULD acquisition (0.16 \pm 0.006mSv) with iterative reconstruction and a standard dose filtered back projection acquisition (11.2 \pm 2.7mSv), and more nodules detected with model based iterative reconstruction (MBIR) than adaptive statistical iterative reconstruction (ASIR) (16). MBIR is known to better minimize image noise compared to ASIR : Ichikawa and al found a significantly lower image noise with LD (1.6 \pm 0.8 mSv) MBIR CT (11.6 \pm 1.0 Hounsfield units (HU)) than with LD ASIR CT (21.1 \pm 2.6 HU, $p < 0.0005$), a slightly better image quality score for decreased lung attenuation lesion, and no difference in image quality scores for consolidation or mass, ground-glass attenuation, or reticular opacity with MBIR compared to ASIR LD CT (8). But MBIR may slightly deteriorate lesion margin (9), and significantly increases reconstruction time, taking more than 30 minutes, when patients lie less than 10 minutes in the machine. ASIR-V is the latest generation of hybrid iterative reconstruction (GE medical Healthcare, Milwaukee, WI). It combines ASIR and MBIR and enables a better noise reduction than ASIR, with a processing time of only few minutes, suitable to a routine chest CT session (17).

According to the ALARA (as low as reasonably achievable) principle, we hope to validate our ULD chest CT protocol (<0.2mSv), the dose of which is 10 times lower than a usual LD CT, as a sensitive

1
2 143 tool to detect lung nodules. Thus, this ULD CT acquisition could be generalized for lung nodules
3
4 144 detection and would consolidate the setup of lung cancer screening programs. Also, this would allow
5
6 145 the generalization of ULD protocols, for radiation sensitive populations (children and young adults
7
8
9 146 in particular).

10
11 147
12

13
14 148 **METHODS AND ANALYSIS**

15
16 149 **Study design and objectives**

17
18 150 The objectives of this study are to evaluate the performance of ULD CT for the detection of lung
19
20 151 nodules, and the evaluation of nodule characteristics in comparison to LD CT. Furthermore, as
21
22
23 152 smoking is a common risk factor, performance for the detection of cardiac and respiratory associated
24
25 153 diseases (bronchial abnormalities, emphysema, coronary calcifications) is also evaluated.

26
27 154 An additional ULD CT is performed in patients referred for non-enhanced chest CT for lung nodules
28
29
30 155 check-up or follow-up. The dose delivered with both acquisitions is still lower than the French
31
32 156 diagnostic reference level (6.65mSv). We chose to only include nodules ≥ 4 mm as the incidence of
33
34 157 cancer is very low below this threshold, and are not currently considered as clinically significant (18).
35
36 158 Nodules < 3 mm are considered as micronodules and the recommendation from the Fleischner Society
37
38
39 159 recommends that such nodules should not be measured, given inherent accuracy limitations and
40
41 160 variability in determining whether the lesion is a solid, part-solid, or ground-glass nodule (19). A 4
42
43 161 mm threshold was also used for the NLST study (2). In addition, fully calcified nodules are excluded
44
45
46 162 from the analysis because they are constantly benign and easily detected.

47
48 163 We will study nodule subtypes (solid, part-solid and pure ground-glass) and size. Furthermore we
49
50 164 will evaluate the performance of ULD CT to diagnose intrapulmonary lymph nodes, which are benign
51
52
53 165 nodules not needing follow up (20), and were not analyzed in previous ULD CT studies.

54
55 166 This trial sponsored by the Grenoble-Alpes University Hospital (CHUGA, France) is designed as a
56
57 167 monocentric, prospective, non-randomized study in which the patient is his own control. All
58
59
60 168 outcomes are evaluated by blinded double reading. Patient enrollment started in October 2017 and is

expected to be completed in September 2018. [Figure 1](#) summarizes the process of inclusion, intervention and reading, described in detail below.

Primary outcome

Detection rate (sensitivity) of lung nodules in ULD chest CT using the conventional chest LD CT as gold-standard.

Secondary outcomes

- 1) Diagnostic criteria: true positive (TP), false positive (FP), true negative (TN), false negative (FN), positive predictive value (PPV), negative predictive value (NPV), Specificity (Sp) of ULD CT
- 2) Concordance of nodule's size, subtype, and diagnosis of typical intrapulmonary lymph node among lung nodules between ULD and LD CT
- 3) Inter-observer reproducibility for size, subtype and diagnosis of lung nodules in ULD CT
- 4) Influence of subjects characteristics (age, sex, BMI), nodule location, and nodule size on lung nodule detection with ULD CT
- 5) Concordance of emphysema detection, type and distribution between ULD and LD CT
- 6) Concordance of Weston score of coronary calcifications between ULD and LD CT
- 7) Concordance of visual assessment of bronchial thickening, mucoid impaction or dilatation between ULD and LD CT

Eligibility Criteria

Inclusion criteria

- aged 18 years or older
- referred for non-enhanced chest CT for the following indications:
 - lung nodule check-up or follow-up
 - nodular abnormality on chest X ray
 - morphologic assessment of chronic obstructive pulmonary disease (COPD) or emphysema

- asbestos exposure
- assessment before lung radio frequency ablation
- assessment of disease extent of an extra thoracic cancer (in case of iodinated intravenous contrast agent contraindication)
- Check-up before extra-thoracic transplantation (in case of iodinated intravenous contrast agent contraindication).

Exclusion criteria

- Inability to lie down and stay still during the examination
- Inability to hold breath for more than 5 seconds
- Pneumonia in the last 3 months
- Body mass index (BMI) more than 35kg/m²
- Pregnant or breastfeeding women

CT scan acquisitions and reconstructions

The LD and ULD acquisitions are performed on the Revolution CT scanner (GE medical Healthcare, Milwaukee, WI, USA) equipped with the third generation ASIR-V iterative reconstruction. Acquisitions are performed successively in the same CT exam, in the supine position and at suspended full inspiration. Both acquisitions cover the same pulmonary fields from the apex to the costo-diaphragmatic angle, determined on the scout views (2 views).

The LD acquisition is the reference exam for the diagnosis of pulmonary nodules. The acquisition parameters are: spiral CT scanning; 120kVp; automatic modulation of 3D radiation dose (“Smart mA”+ Organ Dose Modulation) with lower bound 100mA, maximal bound 200mA and noise index 10; rotation time: 0.35sec ; modulation 35-70 mAs; pitch = 0.992 :1 and collimation: 80mm. The radiation dose, CTDIvol (volume CT dose index) and DLP (Dose Length Product = CTDIvol x length of exposure) may vary depending on patient attenuation and length of the acquisition. The expected

DLP is between 70 and 200mGy.cm (0.98mSv to 2.8mSv) (the effective dose is calculated by multiplying DLP by a thoracic conversion factor of 0.014 (21)), for an average DLP of 100mGy.cm. The ULD CT acquisition parameters are: spiral CT scanning; 120kVp; fixed tube current of 10mA; rotation time: 0.35s; 3.5 mAs; pitch: 0.992 :1, collimation: 80mm. These parameters are fixed for all patients. The CTDIvol is constant at 0.24mGy. The DLP will depend only on the length of the acquired chest, different for each patient, expected around 10mGy.cm (0.14mSv). The modulation of the mA is deactivated to allow a very low tube current and therefore an ULD acquisition. The ULD acquisition increases the exam time by up to two minutes.

The reconstruction parameters are identical for both acquisitions: slice thickness: 1.25mm; standard filter and lung filter; contiguous 8-mm thickness Maximal Intensity projection (MIP) reconstruction, and iterative reconstruction with different percentages. We use ASIR-V in our study which is the latest generation of iterative reconstruction techniques. It blends hybrid iterative reconstruction and standard filtered back projection. The percentage of ASIR-V represents the amount of iterative reconstruction, from 0% (filtered back projection only) to 100% iterative reconstruction, which modifies image noise and texture. When designing our study, ASIR-V was not yet studied for chest CT. The CT vendor engineers suggested an empirical percentage between 40 up to 100%, depending on radiologist practice and preferences. We decided to test percentages of iterative reconstruction of 50% and 100%. The LD CT images are reconstructed with 50% ASIR-V (LD) and the ULD CT images with 50% (ULD50) and 100% (ULD100) ASIR-V.

The statistical analyses will be performed twice: with ULD50 and ULD100.

For every patient, CTDIvol and DLP are recorded. Effective dose and Size Specific Dose Estimates (SSDE) will be then calculated. Concerning the additional radiation for included patients, our ULD CT protocol has an expected effective dose between 0.10 and 0.20 mSv, which is about 6 to 20 times lower than the LD protocol (which is the usual dose in our institution for this indication), similar to a 2-views CXR, and to 30 days of natural radiation (22). Moreover, total dose of the entire exam (around 1.1 to 3 mSv) is lower than French diagnostic reference level of 6.65mSv.

Recruitment and intervention

Patients included in the study are those referred for a diagnostic chest CT without contrast media injection. On the day of the CT scan, a radiologist checks the eligibility criteria for the study, and informs the patient who signs a participation consent form if he accepts to join the study. The radiologist then collects the following parameters: height, weight, history of oncology, cardio-respiratory pathology and exposure to smoking. The patient then undergoes the standard diagnostic LD CT acquisition followed by the ULD acquisition. If, however, the dose of the LD acquisition is greater than 6.65mSv (French diagnostic reference level), the ULD acquisition is not performed and the patient is excluded from the data analysis. The patient's participation in the study is completed once he leaves the examination room.

The CT images of the LD acquisition are analysed by the radiologist who gives his medical report for the patient's medical management. If the number of nodules ≥ 4 mm identified on this acquisition is ≥ 6 in one lung, the patient will be excluded from the data analysis because the analysis of the outcomes will be too complicated to implement.

Patient and Public Involvement

Patients or public were not directly involved in the development of the research question. However, lowering the radiation dose is a rising concern for the patients and for public health. Patients were also not directly involved in the design, the recruitment and the conduct of this study.

As a regular medical care, the report of the diagnostic LD CT is sent to the prescribing physician, and to the patients at their request. According to French law, patients will be informed of the global results of the study at their request.

Blind reading of outcomes

For LD, ULD50 and ULD100 reconstructions, 2 radiologists will independently read all the radiological parameters. In order to limit the number of exams assessed by each reader, 4 radiologists

split into 2 pairs will participate in the blind reading. Each pair of radiologists (1 junior and 1 senior radiologist) reads the three sets of images for the same patient in a random order.

The term “blind” means that radiologists have neither knowledge of the patient's identity nor access to the results of diagnostic reading. To avoid patient identification, CT acquisitions are anonymized by deleting in the DICOM fields: the name, age and date of birth of the patient; the date and time of the examination and the name of the referring radiologist for the diagnosis. Each patient reconstruction is identified by a random number that differs for each of the two readers. Radiologists never read two series of the same patient consecutively.

Anonymized exams are periodically transmitted to a pair with at least 15 LD, 15 ULD50 and 15 ULD100 reconstructions. The three patient reconstructions are not necessarily given the same day to both radiologists. In addition, the order of presentation is not identical for the two radiologists.

The reading is performed on a diagnostic console (IMPAX software, 6.5.5.3502) (Agfa, Belgium) using Barco MDNC-3121 monitors (Barco, Courtrai, Belgium) and includes mediastinal and parenchymal filter reconstructions for each acquisition. The radiologist is free to adapt the level and width of the window to its reading practice (initial parenchymal window defined by a width of 1500UH and a level of -600UH), and to perform multiplanar reconstructions in the different plans of space. The reading also includes the additional MIP reconstruction for each acquisition, in order to sensitize the detection of nodules (23) (this type of reading from MIP series is performed in clinical routine).

Radiologists identify nodules of longer diameter ≥ 4 mm by locating them with the slice number and the lobe. It is known that each lung has three lobes (right upper lobe, middle lobe, right lower lobe, culmen, lingula, and left lower lobe). Each radiologist completes a reading grid for each reconstruction with all detected nodule characteristics, evaluation of emphysema, coronary calcification and bronchial abnormalities.

The completed grids are given to a Clinical Research Assistant for data entry and identification of discrepancies in identification of nodules between the two radiologists.

- 1
2 299 We consider that a nodule is the same between the two readers if:
3
4 300 • it is located in the same lobe
5
6
7 301 • the slice number is identical at ± 5 slices (a nodule will be visible on several successive slices)
8
9 302 • the longest diameter of nodule is the same at ± 2 mm (24)

11 303 If these criteria are not respected or if a radiologist identifies one or more nodules in addition to or
12
13 304 less than the second radiologist, a consensus with a third CHUGA senior thoracic radiologist with 27
14
15
16 305 years of experience is obtained. This third radiologist is not part of the reading pairs. The consensus
17
18 306 is made from anonymized reconstructions and the reconstructions of the same patient are not
19
20
21 307 processed successively.

22
23 308 Besides, for every reconstruction is recorded:

- 24
25 309 - noise by measuring standard deviation in a region of interest placed in the tracheal air above
26
27 310 the carina,
28
29
30 311 - shape of the trachea which indicates inspiration degree,
31
32 312 - subjective image quality on a 3-point scale.
33
34 313

35
36
37 314 **Data monitoring**

38
39 315 All data is monitored by Grenoble-Alpes University Hospital (trial sponsor), in order to verify that
40
41 316 for every patient enrolled there is a signed consent form and that the inclusion and exclusion criteria
42
43
44 317 are respected. In addition all data collected in the case report form of every enrolled patient are
45
46 318 verified.
47

48 319
49
50 320 **Sample size**

51
52
53 321 With a 90% power, to have a sensitivity of detection of nodules with the ULD CT to 90% with a
54
55 322 confidence interval to $\pm 10\%$, it would be necessary to analyze 124 nodules. According to a
56
57 323 retrospective analysis of patients with indication of pulmonary nodule CT made at CHUGA, out of
58
59
60 324 420 patients per year with this indication, 210 present pulmonary nodules with a total of about 400

nodules. It should therefore include about 140 patients to have 124 nodules to be analyzed. Considering a 5% potential loss to follow-up or withdrawal of consent, the actual number of subjects to include is 147 in total. To this are added three potential patients who could be secondarily excluded from the study for a number of nodules ≥ 6 in one of the lungs. The total number of patients to include is 150. The sample size calculations were carried out using R software version 3.1.0 (library MKmisc, function power.diagnostic.test) (25, 26, 27).

Statistical analysis

In this non-randomized study where each patient is his own control, the threshold $p < 0.05$ will be taken into account to define the significance of the statistical tests. Analyses will be carried out in accordance with good statistical analysis practices after freezing of the database and will be carried out with the software R (version $\geq 3.1.0$).

The normality of the dependent quantitative parameters will be determined by the Shapiro-Wilks test or by graphical verification of the symmetry of the distribution. When the normality of the distribution of such a parameter has been demonstrated, it will be described by its mean and its standard deviation. Otherwise it will be described by its median, the 25th and the 75th percentile. The qualitative parameters will be expressed in number and percentage.

For the main objective, the sensitivity of the ULD CT (compared to the LD CT) for the detection of nodules will be calculated and accompanied by a 95% confidence interval. For secondary objective 1, the number of TP, FP, TN, FN, PPV, NPV and Sp of the ULD CT (compared to LD CT) will be calculated. For secondary objectives 2, 5, 6 and 7, the concordance of the qualitative variables will be evaluated using the kappa coefficient. The concordance of the quantitative variables will be evaluated using Lin's concordance coefficient. For each coefficient, the 95% confidence interval will be given. For secondary objective 3, inter-observer reproducibility for qualitative variables will be evaluated using the kappa coefficient. It will be evaluated, for the quantitative variables, using the ICC (intra class coefficient). For each coefficient, the 95% confidence interval will be given. For

1
2 351 secondary objective 4, a logistic regression model will be implemented. The variable to be explained
3
4 352 will be the result of detecting each nodule in ULD CT compared to the LD CT (0 = good detection /
5
6 353 1 = bad detection). The explanatory variables will be the age, sex and BMI of the patient, the location
7
8
9 354 (lobe) and the size of the nodule. The size of the nodule can be used as a qualitative variable (<5mm,
10
11 355 5-10mm,> 10mm).
12
13 356 An interim analysis including the analysis of the primary endpoint will be performed after inclusion
14
15
16 357 of the first 50 patients. This interim analysis will aim to: decide whether to continue or stop the study
17
18 358 for futility and readjust the number of patients if necessary (if the characteristics of the patients
19
20 359 included do not correspond to those initially planned (too many patients without nodules ≥ 4 mm)).
21
22
23 360 In order to maintain an overall threshold of 5% in the final analysis, the interim analysis will be
24
25 361 carried out with a threshold of 0.1% (28). The results of the interim analysis will be taken into account
26
27 362 by the steering committee to propose modifications to the analysis plan. For this interim analysis,
28
29
30 363 data from the confrontation between the two radiologists will be used.
31
32 364
33

34 365 **Limitations**

36 366 First limitation of our protocol is that we do not have a true screening population because there is no
37
38
39 367 organized lung cancer screening program in our country yet. Therefore, our study population
40
41 368 corresponds to patients routinely referred for lung nodule checkup or follow up instead of a risk-
42
43 369 factor based population.
44
45
46 370 Another limitation is that ULD CT is easily recognizable as the image noise is increased as compared
47
48 371 to LD CT, as well as ULD 50 and ULD 100 are possible to distinguish for an experienced radiologist.
49
50 372 As a consequence, readers were not blinded for these, but for patient name, sex, age, clinical status,
51
52 373 and CT report.
53
54
55 374 Recall bias is limited by a randomized order of presentation and cutting into several reading sessions.
56
57 375 Although we wanted to have a “western population”, we decided not to include obese patients with a
58
59 376 BMI>35, because ULD CT are of poorer quality, due to the need of more radiation-exposure to
60

produce acceptable images. Vardhanabhuti and al. recently found a loss of nodule detection with iterative reconstructed CT scanners at an effective dose of $0.14 \pm 0.01 \text{ mSv}$ for obese patients with BMI > 38 (29).

We decided to test percentage of 50 and 100% of ASIR-V. Tang and al. tested ASIR-V from 10 to 100% in non-enhanced chest and showed ASIR-V has greater potential in reducing image noise and artifacts and maintaining image sharpness when compared to ASIR, and 60% ASIR-V had the highest image quality combining both the objective and subjective evaluation of images (30). This finding, although occurring after the design of our study is close to our chosen 50% level of ASIR-V.

Finally, our study has been conceived before the recommendations of the EU Position statement published at the end of 2017(31). Therefore, we measured manually the nodules instead of using computerized volumetry.

FUNDING

This trial is funded by the Delegation to Clinical Research and Innovation (DRCI) of Grenoble-Alpes University Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

AUTHOR CONTRIBUTIONS

M. Ludwig is the corresponding author and contributed to the conception of the study, to the inclusion of patients, to the blind reading of outcomes and to the drafting of the manuscript.

E. Chipon contributed to the conception of the study, to the drafting of the manuscript, and is responsible for data management and its integrity.

J. Cohen contributed to the conception of the study, to the inclusion of patients, to the blind reading of outcomes and to the revision of the manuscript.

1
2 402 E. Reymond contributed to the inclusion of patients, to the blind reading of outcomes and to the
3
4 403 revision of the manuscript.
5
6 404 M. Medici contributed to the design and application of statistical analysis, and to the drafting of the
7
8
9 405 manuscript.
10
11 406 A. Cole contributed to the blind reading of outcomes and to the revision of the manuscript.
12
13 407 A. Moreau Gaudry contributed to the conception of the study and to the revision of the manuscript.
14
15
16 408 G R Ferretti is the principal investigator of the study and contributed to the conception of the work,
17
18 409 to the inclusion of patients, to the blind consensus of outcomes and to the revision of the manuscript.
19
20 410 All authors approved the final manuscript and agreed to be accountable for all aspects of the work.
21
22
23 411

24
25 412 **COMPETING INTERESTS**

26
27 413 The authors declare that they have no competing interests
28
29
30 414

31
32 415 **CONSENT FOR PUBLICATION**

33
34 416 Not applicable
35
36
37 417

38
39 418 **ETHICS AND DISSEMINATION**

40
41 419 This trial is registered on the ClinicalTrials.gov database (reference NCT03305978) (see
42
43 420 supplementary file “trial registration data set”), and was approved by the relevant ethical committee
44
45
46 421 (Comité de Protection des Personnes, CPP sud-est VI, France, 07/07/2017, CPP Reference: AU1342).
47
48 422 The Protocol version is N°1.0- Date: May 4th 2017
49
50 423
51
52 424 All patients sign a consent form before being enrolled in the trial, in accordance with the Declaration
53
54
55 425 of Helsinki II.
56
57 426 Once the statistical report is finalized, we plan to publish our results in an international scientific
58
59
60 427 journal and present them in national and international congresses.

DATA STATEMENT

Legal restrictions (French personal data laws) prohibit the authors from making the minimal data set publicly available. These data are available upon request.

ACKNOWLEDGEMENTS

The authors thank Alexandre Rey and Pierre Pittet for their help to collect and prepare data, Tarek Ittobane for data monitoring, Dr A. Jankowski for the inclusion of patients, and Laura Cotarla for English proofreading.

REFERENCES

1. Globocan : Lung Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx)
2. National Lung Screening Trial Research Team, Denise R. Aberle, Amanda M. Adams, Christine D. Berg, William C. Black, Jonathan D. Clapp, Richard M. Fagerstrom, et al.
“Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening.” *The New England Journal of Medicine* 365, no. 5 (August 4, 2011): 395–409.
doi:10.1056/NEJMoa1102873
3. Yousaf-Khan U, van der Aalst C, de Jong PA, et al.”Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval.” *Thorax* 2017;72:48-56. 10.1136/thoraxjnl-2016-208655
4. Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation and National Research Council. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, D.C: The National Academies Press; 2006

5. Kubo T, Ohno Y, Seo JB, Yamashiro T, Kalender WA, Lee CH, et al. "Securing safe and informative thoracic CT examinations-Progress of radiation dose reduction techniques". *Eur J Radiol*. 2017 Jan;86:313–9.
6. Kim, Yookyung, Yoon Kyung Kim, Bo Eun Lee, SeokJeong Lee, YonJuRyu, Jin Hwa Lee, and Jung Hyun Chang. "Ultra-Low-Dose CT of the Thorax Using Iterative Reconstruction: Evaluation of Image Quality and Radiation Dose Reduction." *AJR. American Journal of Roentgenology* 204, no. 6 (June 2015): 1197–1202. doi:10.2214/AJR.14.13629.
7. Vardhanabhuti, Varut, Robert J. Loader, Grant R. Mitchell, Richard D. Riordan, and Carl A. Roobottom. "Image Quality Assessment of Standard- and Low-Dose Chest CT Using Filtered Back Projection, Adaptive Statistical Iterative Reconstruction, and Novel Model-Based Iterative Reconstruction Algorithms." *AJR. American Journal of Roentgenology* 200, no. 3 (March 2013): 545–52. doi:10.2214/AJR.12.9424.
8. Ichikawa, Yasutaka, Kakuya Kitagawa, Naoki Nagasawa, Shuichi Murashima, and Hajime Sakuma. "CT of the Chest with Model-Based, Fully Iterative Reconstruction: Comparison with Adaptive Statistical Iterative Reconstruction." *BMC Medical Imaging* 13 (2013): 27. doi:10.1186/1471-2342-13-27.
9. Padole, Atul, Sarabjeet Singh, Jeanne B. Ackman, Carol Wu, Synho Do, Sarvenaz Pourjabbar, Ranish Deedar Ali Khawaja, et al. "Submillisievert Chest CT with Filtered Back Projection and Iterative Reconstruction Techniques." *AJR. American Journal of Roentgenology* 203, no. 4 (October 2014): 772–81. doi:10.2214/AJR.13.12312.
10. Montet, Xavier, Anne-Lise Hachulla, Angeliki Neroladaki, Frederic Lador, Thierry Rochat, Diomidis Botsikas, and Christoph D. Becker. "Image Quality of Low mA CT Pulmonary Angiography Reconstructed with Model Based Iterative Reconstruction versus Standard CT Pulmonary Angiography Reconstructed with Filtered Back Projection: An Equivalency Trial." *EuropeanRadiology* 25, no. 6 (June 2015): 1665–71. doi:10.1007/s00330-014-3563-5.

11. Yoon, Hyun Jung, Myung Jin Chung, Hye Sun Hwang, Jung Won Moon, and Kyung Soo Lee. “Adaptive Statistical Iterative Reconstruction-Applied Ultra-Low-Dose CT with Radiography-Comparable Radiation Dose: Usefulness for Lung Nodule Detection.” *Korean Journal of Radiology* 16, no. 5 (October 2015): 1132–41. doi:10.3348/kjr.2015.16.5.1132
12. Sui, Xin, Felix G. Meinel, Wei Song, Xiaoli Xu, Zixing Wang, Yuyan Wang, Zhengyu Jin, Jiahong Chen, Rozemarijn Vliegenthart, and U. Joseph Schoepf. “Detection and Size Measurements of Pulmonary Nodules in Ultra-Low-Dose CT with Iterative Reconstruction Compared to Low Dose CT.” *European Journal of Radiology* 85, no. 3 (March 2016): 564–70. doi:10.1016/j.ejrad.2015.12.013
13. Nagatani Y, Takahashi M, Murata K, Ikeda M, Yamashiro T, Miyara T, Koyama H, Koyama M, Sato Y, Moriya H, et al “Lung nodule detection performance in five observers on computed tomography (CT) with adaptive iterative dose reduction using three-dimensional processing (AIDR 3D) in a Japanese multicenter study: Comparison between ultra-low-dose CT and low-dose CT by receiver-operating characteristic analysis”. *Eur J Radiol.* 2015 Jul; 84(7):1401-12. Epub 2015 Apr 2
14. Huber, Adrian, Julia Landau, Lukas Ebner, Yanik Bütikofer, Lars Leidolt, Barbara Brela, Michelle May, Johannes Heverhagen, and Andreas Christe. “Performance of Ultralow-Dose CT with Iterative Reconstruction in Lung Cancer Screening: Limiting Radiation Exposure to the Equivalent of Conventional Chest X-Ray Imaging.” *EuropeanRadiology*, January 26, 2016. doi:10.1007/s00330-015-4192-3
15. Messerli M, Kluckert T, Knitel M, Wälti S, Desbiolles L, Rengier F, et al. “Ultralow dose CT for pulmonary nodule detection with chest x-ray equivalent dose - a prospective intra-individual comparative study”. *EurRadiol.* 2017 Aug;27(8):3290–9.
16. Neroladaki, Angeliki, Diomidis Botsikas, Sana Boudabbous, Christoph D. Becker, and Xavier Montet. “Computed Tomography of the Chest with Model-Based Iterative Reconstruction

- Using a Radiation Exposure Similar to Chest X-Ray Examination: Preliminary Observations.”
European Radiology 23, no. 2 (February 2013): 360–66. doi:10.1007/s00330-012-2627-7.
17. De Marco P, Origgi D. “New adaptive statistical iterative reconstruction ASiR-V: Assessment of noise performance in comparison to ASiR”. *J Appl Clin Med Phys*. 2018 Mar;19(2):275-286. doi: 10.1002/acm2.12253. Epub 2018 Jan 24. PubMed PMID: 29363260; PubMed Central PMCID: PMC5849834
18. Gierada DS, Pinsky P, Nath H, Chiles C, Duan F, Aberle DR. “Projected outcomes using different nodule sizes to define a positive CT lung cancer screening examination”. *J Natl Cancer Inst*. 2014;106:dju284
19. Bankier A, MacMahon H, Goo JM, et al. Recommendations for Measuring Pulmonary Nodules at CT: A Statement from the Fleischner Society. *Radiology* 2017;285:584-600 doi:10.1148/radiol.2017162894
20. Ahn MI, Gleeson TG, Chan IH et-al. “Perifissural nodules seen at CT screening for lung cancer”. *Radiology*. 2010;254 (3): 949-56. doi:10.1148/radiol.09090031
21. Task Group on Control of Radiation Dose in Computed Tomography. “Managing Patient Dose in Computed Tomography. A Report of the International Commission on Radiological Protection.” *Annals of the ICRP* 30, no. 4 (2000): 7–45
22. Exposition de la population française aux rayonnements ionisants liée aux actes de diagnostic médical en 2012. Rapport IRSN PRP-HOM N°2014-6
23. Jankowski, A., T. Martinelli, J. F. Timsit, C. Brambilla, F. Thony, M. Coulomb, and G. Ferretti. “Pulmonary Nodule Detection on MDCT Images: Evaluation of Diagnostic Performance Using Thin Axial Images, Maximum Intensity Projections, and Computer-Assisted Detection.” *European Radiology* 17, no. 12 (December 2007): 3148–56. doi:10.1007/s00330-007-0727-6.


24. Revel MP, Bissery A, Bienvenu M, Aycard L, Lefort C, Fria G. Are two-dimensional CT measurements of small noncalcified pulmonary nodules reliable? *Radiology*. 2004 May;231(2):453-8. PubMed PMID: 15128990.
25. A. Flahault, M. Cadilhac, and G. Thomas (2005). Sample size calculation should be performed for design accuracy in diagnostic test studies. *Journal of Clinical Epidemiology*, 58(8):859-862.
26. H. Chu and S.R. Cole (2007). Sample size calculation using exact methods in diagnostic test studies. *Journal of Clinical Epidemiology*, 60(11):1201-1202.
27. M.R. Chernick and C.Y. Liu (2002). The saw-toothed behavior of power versus sample size and software solutions: single binomial proportion using exact methods. *Am Stat*, 56:149-155.
28. Kenneth F Schulz, David A Grimes. Multiplicity in randomised trials II: subgroup and interim analyses. *Lancet* 2005; 365: 1657–61
29. Vardhanabhuti V, Pang CL, Tenant S, Taylor J, Hyde C, Roobottom C. “Prospective intra-individual comparison of standard dose versus reduced-dose thoracic CT using hybrid and pure iterative reconstruction in a follow-up cohort of pulmonary nodules-Effect of detectability of pulmonary nodules with lowering dose based on nodule size, type and body mass index”. *Eur J Radiol*. 2017 Jun;91:130-141. doi: 10.1016/j.ejrad.2017.04.006
30. Tang H, Yu N, Jia Y, Yu Y, Duan H, Han D, et al. “Assessment of noise reduction potential and image quality improvement of a new generation adaptive statistical iterative reconstruction (ASIR-V) in chest CT”. *Br J Radiol*. 2018 Jan;91(1081):20170521
31. Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. *Lancet Oncol* 2017;18: e754–66. [http://dx.doi.org/10.1016/S1470-2045\(17\)30861-6](http://dx.doi.org/10.1016/S1470-2045(17)30861-6)

FIGURE 1 legend:

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Study Flow chart. ASIR-V[®], adaptive statistical iterative reconstruction-Véo (GE medical
Healthcare, Milwaukee, WI, USA); CT, computed tomography; LD, low dose; LD50, low
dose CT with 50% ASIR-V reconstruction; ULD, ultra-low dose; ULD50, ultra-low dose CT
with 50% ASIR-V reconstruction, ULD 100, ultra-low dose CT with 100% ASIR-V
reconstruction

Figure 1



Study Flow chart. ASIR-V ®, adaptive statistical iterative reconstruction-Véo (GE medical Healthcare, Milwaukee, WI, USA); CT, computed tomography; LD, low dose; LD50, low dose CT with 50% ASIR-V reconstruction; ULD, ultra-low dose; ULD50, ultra-low dose CT with 50% ASIR-V reconstruction, ULD 100, ultra-low dose CT with 100% ASIR-V reconstruction.

210x297mm (300 x 300 DPI)

Trial registration data set :

Primary registry and trial identifying number	ClinicalTrials.gov NCT03305978
Date of registration in primary registry	September 26, 2017
Secondary identifying numbers	38RC17.132
Source(s) of monetary or material support	University Hospital, Grenoble
Primary sponsor	University Hospital, Grenoble
Secondary sponsor(s)	French Thoracic Imaging Society
Contact for public queries	Emilie CHIPON, PhD, +33476767313, echipon@chu-grenoble.fr
Contact for scientific queries	Gilbert FERRETTI, MD PhD, +3376767313, gferretti@chu-grenoble.fr
Public title	Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan.
Scientific title	Detection of Pulmonary Nodules: Comparison of Ultra-low-dose Chest CT (Approaching a Two Views Chest X-ray Radiation) and Standard Low Dose CT. A Monocentric, Prospective, Non-randomized, Comparative, Open-label Study With Blind Reading of the Judgment Criteria
Country of recruitment	France
Health condition(s) or problem(s) studied	Lung cancer screening, radiation exposure
Intervention(s)	<p><u>Device: Ultra low dose chest CT</u> An additional ultra low dose CT row is performed for every subject besides standard diagnostic low dose chest CT. Other Name: Revolution CT (GE Healthcare) 442507CN0, equipped with ASIR V</p> <p><u>Device: Low dose chest CT</u> standard diagnostic low dose chest CT Other Name: Revolution CT (GE Healthcare)</p>
Key inclusion and exclusion criteria	<p>Ages eligible for study: ≥ 18 years Sexes eligible for study: both Accepts healthy volunteers: no</p> <p><u>Inclusion criteria :</u> Patients referred for non enhanced chest CT for following indications :</p> <ul style="list-style-type: none"> - lung nodule search or control - nodular abnormality on chest X ray - statement of COPD or emphysema - asbestos exposure - nodule localization before radio frequency ablation - assessment of disease extent of an extra thoracic cancer (in case of iodinated intravenous contrast agent contraindication) - statement before extrathoracic transplantation (in case of iodinated intravenous contrast agent contraindication) <p>Affiliated with the french social security Who signed consent</p> <p><u>Exclusion criteria :</u> Inability to lie down and stay still during the examination Inability to hold breath more than 5 seconds Pneumonia in the last 3 months Body mass index more than 35kg/m² exclusion period of another interventionnal study</p>

	referred for articles L1121-5 to L1121-8 of french public health code Pregnant or breastfeeding women
Study type	<p>Interventional</p> <p><u>Allocation</u>: Non-Randomized</p> <p><u>Intervention Model</u>: Sequential Assignment</p> <p><u>Intervention Model Description</u>: Major Patient Addressed for Thoracic CT without Injection of Contrast</p> <p><u>Masking</u>: Single (Outcomes Assessor)</p> <p><u>Masking Description</u>: blinding evaluation of criteria</p> <p><u>Primary purpose</u>: diagnostic</p>
Date of first enrolment	October 3, 2017
Target sample size	150
Recruitment status	Recruiting
Primary outcome(s)	<p>Ultra low dose CT lung nodule detection sensibility [Time Frame: 22 months]</p> <p>Detection rate (%) of ≥ 4mm lung nodules in ultra low dose chest CT versus standard low</p>
Key secondary outcomes	<ul style="list-style-type: none"> - Ultra low dose CT diagnostic performances of lung nodule detection [Time Frame: 22 months] :true positives, false positives, true negatives, false negatives, positive predictive value, negative predictive value, specificity, of ≥ 4mm lung nodules detection within ultra low dose chest CT versus standard low dose chest CT - Concordance of ≥ 4mm lung nodules characteristics between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : comparison of size, density, type (true nodule or intrapulmonary ganglion) of ≥ 4mm lung nodule between ultra low dose and standard low dose chest CT - Ultra low dose CT inter-observer reproducibility [Time Frame: 22 months] : inter observer reproducibility for size, density and type of ≥ 4mm lung nodule detected in ultra low dose CT - Influence of subjects characteristics, nodule location, and nodule size on detection between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : analysis of subjects characteristics (age, gender, body mass index), ≥ 4mm nodule location, and ≥ 4 mm nodule size on detection between ultra low dose and standard low dose chest CT - Concordance of emphysema characteristics between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : comparison of emphysema detection, type (centrilobular, paraseptal, panlobular, bullous) and distribution between ultra low dose and standard low dose chest CT - Concordance of coronary calcification detection and quantification between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : Comparison of Weston scores between ultra low dose and standard low dose chest CT - Concordance of bronchial abnormalities evaluation between ultra low dose and standard low dose chest CT [Time Frame: 22 months] : comparison of detection of bronchial thickening or dilatation between ultra low dose and standard low dose chest CT
Ethics Review	approved by the relevant ethical committee (Comité de Protection des Personnes, CPP Sud-Est VI, France, CPP Reference: AU1342), on July 7, 2017

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-207

			Page Number
Reporting Item			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	17
Protocol version	#3	Date and version identifier	18
Funding	#4	Sources and types of financial, material, and other support	16
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1;16
Roles and responsibilities:	#5b	Name and contact information for the trial sponsor	2

1	sponsor contact			
2	information			
3				
4	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	16
5	responsibilities:		collection, management, analysis, and interpretation of	
6	sponsor and funder		data; writing of the report; and the decision to submit the	
7			report for publication, including whether they will have	
8			ultimate authority over any of these activities	
9				
10				
11				
12	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	n/a
13	responsibilities:		centre, steering committee, endpoint adjudication	
14	committees		committee, data management team, and other individuals or	
15			groups overseeing the trial, if applicable (see Item 21a for	
16			data monitoring committee)	
17				
18				
19				
20	Background and	#6a	Description of research question and justification for	5
21	rationale		undertaking the trial, including summary of relevant studies	
22			(published and unpublished) examining benefits and harms	
23			for each intervention	
24				
25				
26				
27	Background and	#6b	Explanation for choice of comparators	6
28	rationale: choice of			
29	comparators			
30				
31				
32	Objectives	#7	Specific objectives or hypotheses	7
33				
34				
35	Trial design	#8	Description of trial design including type of trial (eg, parallel	7
36			group, crossover, factorial, single group), allocation ratio,	
37			and framework (eg, superiority, equivalence, non-inferiority,	
38			exploratory)	
39				
40				
41				
42	Study setting	#9	Description of study settings (eg, community clinic,	7
43			academic hospital) and list of countries where data will be	
44			collected. Reference to where list of study sites can be	
45			obtained	
46				
47				
48	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	8
49			eligibility criteria for study centres and individuals who will	
50			perform the interventions (eg, surgeons, psychotherapists)	
51				
52				
53				
54	Interventions:	#11a	Interventions for each group with sufficient detail to allow	10
55	description		replication, including how and when they will be	
56			administered	
57				
58				
59				
60				

1	Interventions:	#11b	Criteria for discontinuing or modifying allocated	11
2	modifications		interventions for a given trial participant (eg, drug dose	
3			change in response to harms, participant request, or	
4			improving / worsening disease)	
5				
6				
7				
8	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	n/a
9	adherence		and any procedures for monitoring adherence (eg, drug	
10			tablet return; laboratory tests)	
11				
12				
13	Interventions:	#11d	Relevant concomitant care and interventions that are	n/a
14	concomitant care		permitted or prohibited during the trial	
15				
16				
17	Outcomes	#12	Primary, secondary, and other outcomes, including the	8
18			specific measurement variable (eg, systolic blood pressure),	
19			analysis metric (eg, change from baseline, final value, time	
20			to event), method of aggregation (eg, median, proportion),	
21			and time point for each outcome. Explanation of the clinical	
22			relevance of chosen efficacy and harm outcomes is strongly	
23			recommended	
24				
25				
26				
27				
28	Participant timeline	#13	Time schedule of enrolment, interventions (including any	7
29			run-ins and washouts), assessments, and visits for	
30			participants. A schematic diagram is highly recommended	
31			(see Figure)	
32				
33				
34				
35	Sample size	#14	Estimated number of participants needed to achieve study	13
36			objectives and how it was determined, including clinical and	
37			statistical assumptions supporting any sample size	
38			calculations	
39				
40				
41				
42	Recruitment	#15	Strategies for achieving adequate participant enrolment to	11
43			reach target sample size	
44				
45				
46	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	n/a
47	generation		computer-generated random numbers), and list of any	
48			factors for stratification. To reduce predictability of a random	
49			sequence, details of any planned restriction (eg, blocking)	
50			should be provided in a separate document that is	
51			unavailable to those who enrol participants or assign	
52			interventions	
53				
54				
55				
56				
57	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	n/a
58	concealment		central telephone; sequentially numbered, opaque, sealed	
59				
60				

mechanism		envelopes), describing any steps to conceal the sequence until interventions are assigned	
Allocation: implementation	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	n/a
Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	11
Blinding (masking): emergency unblinding	#17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n/a
Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	12
Data collection plan: retention	#18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	n/a
Data management	#19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	13
Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	13
Statistics: additional analyses	#20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	14
Statistics: analysis population and missing data	#20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	13

1	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	13
2	formal committee		of its role and reporting structure; statement of whether it is	
3			independent from the sponsor and competing interests; and	
4			reference to where further details about its charter can be	
5			found, if not in the protocol. Alternatively, an explanation of	
6			why a DMC is not needed	
7				
8				
9				
10				
11	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	14
12	interim analysis		including who will have access to these interim results and	
13			make the final decision to terminate the trial	
14				
15				
16	Harms	#22	Plans for collecting, assessing, reporting, and managing	n/a
17			solicited and spontaneously reported adverse events and	
18			other unintended effects of trial interventions or trial conduct	
19				
20				
21	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	n/a
22			and whether the process will be independent from	
23			investigators and the sponsor	
24				
25				
26				
27	Research ethics	#24	Plans for seeking research ethics committee / institutional	16
28	approval		review board (REC / IRB) approval	
29				
30				
31	Protocol	#25	Plans for communicating important protocol modifications	n/a
32	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
33			relevant parties (eg, investigators, REC / IRBs, trial	
34			participants, trial registries, journals, regulators)	
35				
36				
37	Consent or assent	#26a	Who will obtain informed consent or assent from potential	16
38			trial participants or authorised surrogates, and how (see	
39			Item 32)	
40				
41				
42				
43	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
44	ancillary studies		participant data and biological specimens in ancillary	
45			studies, if applicable	
46				
47				
48	Confidentiality	#27	How personal information about potential and enrolled	n/a
49			participants will be collected, shared, and maintained in	
50			order to protect confidentiality before, during, and after the	
51			trial	
52				
53				
54				
55	Declaration of	#28	Financial and other competing interests for principal	16
56	interests		investigators for the overall trial and each study site	
57				
58				
59	Data access	#29	Statement of who will have access to the final trial dataset,	19
60				

		and disclosure of contractual agreements that limit such access for investigators	
Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	16
Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	n/a
Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a

The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 23. July 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)